A Phase 3 interventional study of Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV) and Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV) in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 14 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one has the largest enrollment of the 18 interventional ones that give a count, is the only one that started in 2008, is one of 9 in phase 3, and was the 5th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:
Takeda · Sites in Japan
Takeda
Ages 6+
By country, each count listing its studies:
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 14 · Phase 4 2
First in 2002; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 47 across the 18 interventional studies, 113 across the 4 observational. Of the 19 that completed or were terminated, 12 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to develop a subcutaneous treatment option for participants with Primary Immunodeficiency Diseases (PID) that allows an administration of Immune Globulin Intravenous (Human), 10% at the same frequency as IV administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
Biological: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
Pharmacokinetics of intravenous (IV) infusions of immune globulin intravenous (IGIV), 10% and efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
Biological: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
Drug page: Hyaluronidase (human recombinant)
Comprises subjects previously participating in Study 160601, who now only complete Study Epoch 2 (subcutaneous \[SC\] infusions) as bioavailability/exposure for intravenous (IV) treatment was already obtained in Study 160601. Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up).
Also known as: HYQVIA
Drug page: Hyaluronidase (human recombinant)
Comprises all other subjects. Study Epoch 1: IV infusion of IGIV, 10% (same dose and frequency as pre-study) to determine pharmacokinetics. Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up).
Validated Acute Serious Bacterial Infection (VASBI) Rate
Serious acute bacterial infections include bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess that are caused by a recognized bacterial pathogen. VASBI rate is the mean number of VASBIs per participant per year, recorded for SC Administration of IGIV, 10%, with rHuPH20 after ramp-up, only. The mean number of VASBIs per participant per year and the 99% upper confidence limit for the acute serious bacterial infection rate were calculated using a Poisson model to account for the length of the observation periods per participant.
Time frame: Throughout the study period (17 months)
Bioavailability (AUC) of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20 in Participants ≥12 Years
Bioavailability expressed as pharmacokinetic (PK) equivalence of immunoglobulin (IgG) in terms of ratio of Area Under the Concentration Curve (AUC)/Week after administration of immune globulin intravenous (IGIV), 10% given via subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up to intravenous (IV) route, i.e. ratio of AUC/week of SC/rHuPH20 versus IV administration of IGIV, 10%. Expressed as a percentage.
Time frame: PK AUC evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion
Bioavailability (Trough Levels) of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20 in Participants Aged 2 to < 12 Years
Bioavailability expressed as pharmacokinetic (PK) equivalence of immunoglobulin (IgG) in terms of trough levels after administration of immune globulin intravenous (IGIV), 10% given via subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up to intravenous (IV) route, i.e. ratio of AUC/week of SC/rHuPH20 versus IV administration of IGIV, 10%. Expressed as a percentage.
Time frame: IgG trough levels measured at baseline and on day of each 3- or 4-week infusion for infusion for IV and SC (except during ramp-up for SC) and at end of study visit
Bioavailability (AUC) of IgG After SC Administration of IGIV, 10%, Given With and Without rHuPH20
Bioavailability of immunoglobulin (IgG) after subcutaneous (SC) administration of immune globulin intravenous (IGIV), 10%, with and without recombinant human hyaluronidase (rHuPH20) (from current study 160603 and study 160601, respectively), as measured by ratio of AUC of IgG per dose/kg with versus without rHuPH20. Expressed as a percentage. This was analysed for participants in Stratum A , participants in Stratum B and for all participants who received IGIV, 10% via SC administration (Stratum A plus Stratum B): Stratum A: Participants who provided data both on SC with AND without rHuPH20 ie, participants who participated in both studies 160601 and 160603; Stratum B: Participants who provided data on SC with OR without rHuPH20, but not on both (participants who participated in study 160601 OR 160603, but not in both studies).
Time frame: PK: 160603 (IV: before infusion (inf.) #4 [3-week treatment interval] or inf. #3 [4-week treatment interval];SC: before last SC inf.) 1 hour pre-inf. ≤28 days (+/-2 days) post-inf.; 160601- 1 hour pre-inf. (before inf. #8) ≤7 days (+/-1 day) post-inf.
Annual Rate of All Infections Per Participant
Annual rate of all infections per participant after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the annual rates will be calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary endpoint.
Time frame: Throughout the study period (17 months)
Trough Levels of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20
Trough levels of immunoglobulin (IgG) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up
Time frame: IgG trough levels measured at baseline and on day of each 3- or 4-week infusion for IV and SC (except during ramp up for SC) and at end of study visit.
Trough Levels of IgG Subclasses After Administration of IGIV, 10% Given Via IV or SC With rHuPH20
Trough levels of immunoglobulin (IgG) subclasses after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up by IgG subclasses 1 to 4 at end of IV treatment and end of SC treatment with rHuPH20 IgG subclass 1 (IgG 1) IgG subclass 2 (IgG 2) IgG subclass 3 (IgG 3) IgG subclass 4 (IgG 4)
Time frame: IgG subclasses (1-4) trough levels measured at baseline and on day of each 3- or 4-week infusion for infusion for IV and SC (except during ramp up for SC) and at end of study visit
Antibody Levels to Tetanus (Clostridium Tetani Toxoid)
Antibody levels to Tetanus (Clostridium tetani toxoid) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20
Time frame: IV: At baseline; SC/rHuPH20: at baseline then at infusion #1 at ramp-up and at infusions #5, 9, 13 (for 3-week treatment interval) and infusions #4, 7, 10 (for 4-week treatment interval), SC: end of SC treatment and at end of study visit
Antibody Levels to Haemophilus Influenzae
Antibody levels to Haemophilus influenzae after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20
Time frame: IV: At baseline; SC/rHuPH20: at baseline then at infusion #1 at ramp-up and at infusions #5, 9, 13 (for 3-week treatment interval) and infusions #4, 7, 10 (for 4-week treatment interval), SC: end of SC treatment and at end of study visit
Antibody Levels to Measles
Antibody levels to measles after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20
Time frame: IV: At baseline; SC/rHuPH20: at baseline then at infusion #1 at ramp-up and at infusions #5, 9, 13 (for 3-week treatment interval) and infusions #4, 7, 10 (for 4-week treatment interval), SC: end of SC treatment and at end of study visit
Antibody Levels to Hepatitis B
Antibody levels to hepatitis B after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20
Time frame: IV: At baseline; SC/rHuPH20: at baseline then at infusion #1 at ramp-up and at infusions #5, 9, 13 (for 3-week treatment interval) and infusions #4, 7, 10 (for 4-week treatment interval), SC: end of SC treatment and at end of study visit
IgG Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older
Minimal immunoglobulin (IgG) concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and Older
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion
IgG Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older
Immunoglobulin (IgG) Area under the Curve (AUC) AUC/week after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 days for 3-week treatment interval or 28 days for 4-week treatment interval).
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
IgG Clearance (CL) for Participants Aged 12 Years and Older
Immunoglobulin (IgG) Clearance after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Clearance (CL) is provided after administration of IGIV,10% given via IV route. Apparent Clearance is provided after administration of IGIV, 10% given via SC route with rHuPH20. Clearance and apparent clearance are determined by weight adjusted dose divided by total AUC.
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
IgG Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older
Maximum immunoglobulin (IgG) concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
IgG Terminal Half Life (T1/2) for Participants Aged 12 Years and Older
Terminal half life (T1/2) for immunoglobulin (IgG) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Terminal half life is the time it takes for the plasma concentration or the amount of immunoglobulin in the body to be reduced by 50% during the terminal phase
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Time to Maximum IgG Concentration (T-max) for Participants Aged 12 Years and Older
Time to Maximum Immunoglobulin (IgG) Concentration (T-max) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Tetanus Antibody Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older
Minimal tetanus (clostridium tetani toxoid) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Tetanus Antibody Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older
Tetanus (clostridium tetani toxoid) antibody Area under the Curve (AUC) AUC/week after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 days for 3-week treatment interval or 28 days for 4-week treatment interval).
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Tetanus Antibody Clearance (CL) for Participants Aged 12 Years and Older
Tetanus (clostridium tetani toxoid) antibody Clearance after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Clearance (CL) is provided after administration of IGIV,10% given via IV route. Apparent Clearance is provided after administration of IGIV, 10% given via SC route with rHuPH20. Clearance (CL) and apparent clearance are determined by weight adjusted dose divided by total AUC.
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Tetanus Antibody Terminal Half Life (T1/2) for Participants Aged 12 Years and Older
Terminal half life (T1/2) for tetanus (clostridium tetani toxoid) antibody after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Terminal half life is the time it takes for the plasma concentration or the amount of tetanus antibody in the body to be reduced by 50% during the terminal phase
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Tetanus Antibody Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older
Maximum tetanus (clostridium tetani toxoid) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Time to Maximum Tetanus Antibody Concentration (T-max) for Participants Aged 12 Years and Older
Time to Maximum tetanus (clostridium tetani toxoid) antibody Concentration (T-max) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
H. Influenzae Antibody Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older
Minimal influenza (haemophilus influenzae) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
H. Influenzae Antibody Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older
Influenza (haemophilus influenzae) antibody Area under the Curve (AUC) AUC/week after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 days for 3-week treatment interval or 28 days for 4-week treatment interval).
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
H. Influenzae Antibody Clearance (CL) for Participants Aged 12 Years and Older
Influenza (haemophilus influenzae) antibody Clearance after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Clearance (CL) is provided after administration of IGIV,10% given via IV route. Apparent Clearance is provided after administration of IGIV, 10% given via SC route with rHuPH20. Clearance (CL) and apparent clearance are determined by weight adjusted dose divided by total AUC.
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval];SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
H. Influenzae Antibody Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older
Maximal influenza (haemophilus influenzae) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
H. Influenzae Antibody Terminal Half Life (T1/2) for Participants Aged 12 Years and Older
Terminal half life (T1/2) for influenza (haemophilus influenzae) antibody after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Terminal half life is the time it takes for the plasma concentration or the amount of influenza antibody in the body to be reduced by 50% during the terminal phase.
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Time to Maximum H. Influenzae Antibody Concentration (T-max) for Participants Aged 12 Years and Older
Time to Maximum influenza (haemophilus influenzae) antibody Concentration (T-max) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
Time frame: PK evaluations: (IV: before infusion #4 [for 3-week treatment interval] or infusion #3 [for 4-week treatment interval]; SC: before last SC infusion) 60 minutes pre-infusion up to 28 days (+/-2 days) post-infusion.
Rate of Days Off School or Work
Monthly rate of days off school or work after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates were calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month were defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.
Time frame: Monthly, for up to 17 months
Rate of Days on Antibiotics
Monthly rate of days on antibiotics after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates were calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month was defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.
Time frame: Monthly, for up to 17 months
Rate of Acute Physician Visits
Monthly rate of acute physician visits after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates will be calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month will be defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.
Time frame: Monthly, for up to 17 months
Rate of Days in Hospital
Monthly rate of days in hospital after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates will be calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month will be defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.
Time frame: Monthly, for up to 17 months
Percentage of Participants for Which the Infusion Rate Was Reduced and/or the Infusion Interrupted or Stopped for Tolerability Concerns or for Adverse Events (AEs)
Percentage of participants for which the infusion rate was reduced and/or the infusion interrupted or stopped during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up for tolerability concerns or for adverse events (AEs). An infusion was deemed as tolerated if there are no serious Adverse Drug Reactions (ADR), no non-serious moderate or severe local ADRs that prevent completion of the infusion and no non-serious moderate or severe systemic ADRs during infusion or within 60 minutes of completion of the infusion.
Time frame: Throughout the study period (17 months)
Percentage of Infusions for Which the Infusion Rate Was Reduced and/or the Infusion Interrupted or Stopped for Tolerability Concerns or for Adverse Events (AEs)
Percentage of infusions for which the infusion rate was reduced and/or the infusion interrupted or stopped during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up for tolerability concerns or for adverse events (AEs). IV administration of IGIV, 10%: 365 infusions; SC administration of IGIV, 10% with rHuPH20: 1129 infusions
Time frame: Throughout the study period (17 months)
Rate of Temporally Associated AEs Per Infusion
Rate of all AEs (including and excluding infections) per infusion that began during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of an infusion ("temporally associated")
Time frame: During infusion or within 72 hours of completion of infusion
Percentage of Participants Reporting ≥1 Temporally Associated AEs
Percentage of participants reporting at least 1 AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")
Time frame: During infusion or within 72 hours of completion of infusion
Percentage of Infusions Resulting in ≥1 Temporally Associated AEs
Percentage of infusions resulting in at least 1 AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")
Time frame: During infusion or within 72 hours of completion of infusion
Percentage of Participants Reporting ≥1 Temporally Associated Moderate or Severe AEs
Percentage of participants reporting at least 1 Moderate or Severe AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")
Time frame: During infusion or within 72 hours of completion of infusion
Percentage of Infusions Resulting in ≥1 Temporally Associated Moderate or Severe AEs Within 72 Hours of Completion of Infusion
Percentage of infusions resulting in at least 1 moderate or severe AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")
Time frame: During infusion or within 72 hours of completion of infusion
Percentage of SC Doses of IGIV, 10% and rHuPH20 Tolerated at 1 Infusion Site
Percentage of subcutaneous (SC) doses of immune globulin intravenous (IGIV), 10% and recombinant human hyaluronidase (rHuPH20) tolerated at 1 infusion site. An infusion was deemed as tolerated if there were no serious adverse drug reactions (ADRs), no non-serious moderate or severe local ADRs that prevented completion of the infusion, and no non-serious moderate or severe systemic ADRs during or within 60 minutes of completion of the infusion.
Time frame: During infusion or within 60 minutes of completion of the infusion
Percentage of Infusions Associated With ≥1 Systemic AE During Infusion or Within 72 Hours of Completion of Infusion
Percentage of intravenous (IV) and subcutaneous (SC) infusions associated with ≥1 systemic AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via IV or SC route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion
Time frame: During infusion or within 72 hours of completion of infusion
Percentage of Participants With ≥1 Systemic AE (Including and Excluding Infections) During Infusion or Within 72 Hours of Completion of Infusion
Percentage of participants with ≥1 systemic AE (including and excluding Infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion
Time frame: During infusion or within 72 hours of completion of infusion
Percentage of Infusions Associated With ≥1 Local AE (Including and Excluding Infections) During Infusion or Within 72 Hours of Completion of Infusion
Percentage of IV and SC (with recombinant human hyaluronidase \[rHuPH20\]) infusions associated with ≥1 local AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with rHuPH20 after ramp-up (during infusion) or within 72 hours of completion of infusion
Time frame: During infusion or within 72 hours of completion of infusion
Percentage of Infusions Associated With ≥1 Local AE At Any Time During the Study
Percentage of intravenous (IV) and subcutaneous (SC) infusions with recombinant human hyaluronidase (rHuPH20) after ramp-up of immune globulin intravenous (IGIV), 10% associated with ≥1 local AE (including and excluding infections) at any time during the study
Time frame: At any time during the study
Percentage of Participants With ≥1 Local AE During Infusion or Within 72 Hours of Completion of Infusion
Percentage of participants With ≥1 local AE (including and excluding Infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion
Time frame: During infusion or within 72 hours of completion of infusion
Percentage of Participants With ≥1 Local AE At Any Time During the Study
Percentage of participants With ≥1 local AE (including and excluding infections) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up at any time during the study
Time frame: During infusion or within 72 hours of completion of infusion
Rate of AEs Determined to be Related to the Study Drug by the Investigator Per Participant
Rate of related AEs defined as the total number of AEs determined by the investigator to be related to the study drug (immune globulin intravenous \[IGIV\], 10% or recombinant human hyaluronidase \[rHuPH20\]), that occur at any time during the study divided by the total number of participants
Time frame: Throughout the study period (17 months)
Rate of AEs Determined to be Related to the Study Drug by the Investigator Per Infusion
Rate of related AEs defined as the total number of AEs determined by the investigator to be related to the study drug (immune globulin intravenous \[IGIV\], 10% or recombinant human hyaluronidase \[rHuPH20\]), that occur at any time during the study divided by the total number of infusions
Time frame: Throughout the study period (17 months)
Frequency of Dose Corrections (If IgG Trough Levels <4.5 g/L) for Each Study Epoch (IV and SC/rHuPH20 Treatment)
Frequency of dose corrections based on immune globulin G (IgG) trough levels \<4.5 g/L IgG, if any, for intravenous (IV) (Epoch 1) and subcutaneous with recombinant human hyaluronidase (SC/rHuPH20) after ramp-up (Epoch 2) administration of immune globulin intravenous (IGIV), 10% Defined/calculated as the number of participants requiring dose adjustments divided by the number of participants, for each respective data set.
Time frame: Throughout the study period (17 months)
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity (A-F)
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD-Attention Deficit/Hyperactivity Disorder BP-Blood Pressure COPD- Chronic Obstructive Pulmonary Disease
Time frame: Throughout the study period (17 months)
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity (G-M)
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe
Time frame: Throughout the study period (17 months)
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity (N-Z)
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Resp.-Respiratory WBC - White blood cells
Time frame: Throughout the study period (17 months)
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Infusion (A-F)
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD-Attention Deficit/Hyperactivity Disorder BP-Blood Pressure COPD- Chronic Obstructive Pulmonary Disease
Time frame: Throughout the study period (17 months)
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Infusion (G-M)
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe
Time frame: Throughout the study period (17 months)
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Infusion (N-Z)
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); ; RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Resp.-Respiratory WBC - White blood cells
Time frame: Throughout the study period (17 months)
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Participant (A-F)
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD-Attention Deficit/Hyperactivity Disorder BP-Blood Pressure COPD- Chronic Obstructive Pulmonary Disease
Time frame: Throughout the study period (17 months)
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Participant (G-M)
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe
Time frame: Throughout the study period (17 months)
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Relatedness to Study Drug, and Severity Per Participant (N-Z)
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Resp.-Respiratory WBC - White blood cells
Time frame: Throughout the study period (17 months)
Percentage of Infusions Associated With ≥1 AE Related to Either or Both Study Drugs
Percentage of Infusions Associated With ≥1 AE Related to immune globulin intravenous (IGIV), 10%, \[administered via intravenous (IV) or subcutaneous (SC) route\], recombinant human hyaluronidase (rHuPH20) or both. The percentage of affected infusions is calculated per subject and then summarized by the median of all subjects analysed.
Time frame: Throughout the study period (17 months)
Percentage of Infusions Tolerated With IV and SC Administration at Dose Used in Study Epoch 2 (SC/rHuPH20 Treatment)
Epoch 2: subcutaneous (SC) administration of immune globulin intravenous (IGIV), 10% with recombinant human hyaluronidase (rHuPH20) after ramp-up. Dose used in Epoch 2 (after ramp-up) was 108% of dose used in intravenous (IV) administration of IGIV, 10%. The percentage of affected infusions is calculated per subject and then summarized by the median of all subjects analysed.
Time frame: Throughout the study period (17 months)
Median Rate of AEs Temporally Associated or Related to Study Drug Per Infusion
Temporally associated defined as during infusion or within 72 hours of completion of infusion. Related defined as determined by investigator to be at least possibly related to study drug (immune globulin intravenous \[IGIV\], 10% or recombinant human hyaluronidase \[rHuPH20\]). Expressed as a percentage.
Time frame: Throughout the study period (17 months)
Number of Participants Who Developed Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20)
Time frame: Throughout the study period (17 months)
Percentage of Participants Who Developed Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20)
Time frame: Throughout the study period (17 months)
Number of Participants Who Experienced a Hemoglobin Drop of >2.0 g/dL, With Evidence of Hemolysis on Further Analysis
Further analysis for incidences of potential hemolysis included direct Coombs' test, free hemoglobin, serum haptoglobin, LDH, urine hemosiderin and microscopic urinalysis
Time frame: Throughout the study period (17 months)
Percentage of Participants Who Experienced a Hemoglobin Drop of >2.0 g/dL, With Evidence of Hemolysis on Further Analysis
Further analysis for incidences of potential hemolysis included direct Coombs' test, free hemoglobin, serum haptoglobin, LDH, urine hemosiderin and microscopic urinalysis
Time frame: Throughout the study period (17 months)
Recruitment was conducted 14 clinical sites in the United States and 1 clinical site in Canada.
| Milestone | 2 to <12 Years | 12 Years and Older |
|---|---|---|
| Started | 14 | 73 |
| Completed | 13 | 71 |
| Not completed | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Participant missed 2 consecutive doses | 0 | 2 |
| Milestone | 2 to <12 Years | 12 Years and Older |
|---|---|---|
| Started | 13 | 71 |
| Completed | 13 | 70 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | 2 to <12 Years | 12 Years and Older |
|---|---|---|
| Started | 13 | 70 |
| Completed | 11 | 70 |
| Not completed | 2 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Geographic factor | 1 | 0 |
| Milestone | 2 to <12 Years | 12 Years and Older |
|---|---|---|
| Started | 11 | 70 |
| Completed | 8 | 60 |
| Not completed | 3 | 10 |
| Withdrew: Adverse event | 1 | 4 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Subject felt increased infections on sc | 0 | 1 |
| Withdrew: Switched to safety follow-up | 0 | 3 |
Serious acute bacterial infections include bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess that are caused by a recognized bacterial pathogen. VASBI rate is the mean number of VASBIs per participant per year, recorded for SC Administration of IGIV, 10%, with rHuPH20 after ramp-up, only. The mean number of VASBIs per participant per year and the 99% upper confidence limit for the acute serious bacterial infection rate were calculated using a Poisson model to account for the length of the observation periods per participant.
| Estimated infections/year | Full Analysis Data Set (FADS) |
|---|---|
| Validated Acute Serious Bacterial Infection (VASBI) Rate | 0.025 |
Bioavailability expressed as pharmacokinetic (PK) equivalence of immunoglobulin (IgG) in terms of ratio of Area Under the Concentration Curve (AUC)/Week after administration of immune globulin intravenous (IGIV), 10% given via subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up to intravenous (IV) route, i.e. ratio of AUC/week of SC/rHuPH20 versus IV administration of IGIV, 10%. Expressed as a percentage.
| Percentage | % Ratio IgG AUC/Week of SC/ IV |
|---|---|
| Bioavailability (AUC) of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20 in Participants ≥12 Years | 93.3 (91.4 to 95.2) |
Bioavailability expressed as pharmacokinetic (PK) equivalence of immunoglobulin (IgG) in terms of trough levels after administration of immune globulin intravenous (IGIV), 10% given via subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up to intravenous (IV) route, i.e. ratio of AUC/week of SC/rHuPH20 versus IV administration of IGIV, 10%. Expressed as a percentage.
| Percentage | %Ratio IgG Trough Level of SC/IV |
|---|---|
| Bioavailability (Trough Levels) of IgG After Administration of IGIV, 10% Given Via IV or SC With rHuPH20 in Participants Aged 2 to < 12 Years | 103.8 (97.5 to 115.4) |
Bioavailability of immunoglobulin (IgG) after subcutaneous (SC) administration of immune globulin intravenous (IGIV), 10%, with and without recombinant human hyaluronidase (rHuPH20) (from current study 160603 and study 160601, respectively), as measured by ratio of AUC of IgG per dose/kg with versus without rHuPH20. Expressed as a percentage. This was analysed for participants in Stratum A , participants in Stratum B and for all participants who received IGIV, 10% via SC administration (Stratum A plus Stratum B): Stratum A: Participants who provided data both on SC with AND without rHuPH20 ie, participants who participated in both studies 160601 and 160603; Stratum B: Participants who provided data on SC with OR without rHuPH20, but not on both (participants who participated in study 160601 OR 160603, but not in both studies).
| Percentage | Ratio IgG AUC of SC With and Without rHuPH20 |
|---|---|
| Participants in Stratum A (N=19) | 118.7 (113.6 to 124.1) |
| Participants in Stratum B (N=54) | 133.6 (118.3 to 150.8) |
| Total Participants (N=73) | 120.4 (115.5 to 125.5) |
Annual rate of all infections per participant after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the annual rates will be calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary endpoint.
| Estimated infections/year | IV Administration of IGIV, 10% | SC Administration of IGIV, 10%, With rHuPH20 After Ramp-up |
|---|---|---|
| Annual Rate of All Infections Per Participant | 4.51 (3.50 to 5.69) | 2.97 (2.51 to 3.47) |
Trough levels of immunoglobulin (IgG) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up
| g/L | Participants Aged 2 to <12 Years | Participants ≥12 Years |
|---|---|---|
| end of IV part | 9.63 (8.29 to 13.60) | 10.40 (9.63 to 11.4) |
| end of SC with rHuPH20 part | 9.95 (7.87 to 15.00) | 10.70 (9.46 to 11.80) |
Trough levels of immunoglobulin (IgG) subclasses after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up by IgG subclasses 1 to 4 at end of IV treatment and end of SC treatment with rHuPH20 IgG subclass 1 (IgG 1) IgG subclass 2 (IgG 2) IgG subclass 3 (IgG 3) IgG subclass 4 (IgG 4)
| mg/dL | Participants Aged 2 to <12 Years | Participants ≥ 12 Years |
|---|---|---|
| IgG 1 end of IV treatment (N=11,69) | 490.0 (414.0 to 752.0) | 574.0 (514.0 to 638.0) |
| IgG 1 end of SC/rHuPH20 treatment (N=11,70) | 455.0 (411.0 to 805.0) | 548.0 (513.0 to 602.0) |
| IgG 2 end of IV treatment (N=11,69) | 327.0 (250.0 to 538.0) | 360.0 (334.0 to 390.0) |
| IgG 2 end of SC/rHuPH20 treatment (N=11,70) | 315.0 (280.0 to 550.0) | 339.0 (318.0 to 374.0) |
| IgG 3 end of IV treatment (N=11,69) | 35.0 (27.0 to 66.0) | 32.0 (27.0 to 37.0) |
| IgG 3 end of SC/rHuPH20 treatment (N=11,70) | 49.0 (26.0 to 83.0) | 36.0 (32.0 to 43.0) |
| IgG 4 end of IV treatment (N=11,69) | 24.0 (16.0 to 55.0) | 14.0 (13.0 to 20.0) |
| IgG 4 end of SC/rHuPH20 treatment (N=11,70) | 23.0 (15.0 to 57.0) | 15.0 (13.0 to 19.0) |
Antibody levels to Tetanus (Clostridium tetani toxoid) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20
| IU/mL | Participants Aged 2 to <12 Years | Participants ≥ 12 Years |
|---|---|---|
| End of IV treatment (N=7,25) | 2.230 (0.0640 to 4.230) | 2.320 (1.810 to 2.710) |
| End of SC/rHuPH20 treatment (N=10,70) | 2.580 (0.990 to 3.810) | 2.525 (2.270 to 2.850) |
Antibody levels to Haemophilus influenzae after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20
| μg/mL | Participants Aged 2 to <12 Years | Participants ≥ 12 Years |
|---|---|---|
| Influenza antibody end of IV treatment (N=7,24) | 2.11 (1.59 to 13.52) | 2.36 (2.05 to 3.05) |
| Influenza antibody end of SC treatment (N=10,70) | 1.97 (1.69 to 4.94) | 2.58 (2.30 to 2.95) |
Antibody levels to measles after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20
| Titer | Participants Aged 2 to <12 Years | Participants ≥ 12 Years |
|---|---|---|
| Measles antibody end of IV treatment (N=0,1) | NA (NA to NA) | 64.0 (NA to NA) |
| Measles antibody end of SC treatment (N=10,70) | 768.0 (256.0 to 2048.0) | 1024.0 (512.0 to 1024.0) |
Antibody levels to hepatitis B after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) at end of IV treatment and end of SC treatment with rHuPH20
| mIU/mL | Participants Aged 2 to <12 Years | Participants ≥ 12 Years |
|---|---|---|
| Hepatitis B antibody end IV treatment (N=6,25) | 212.9 (59.5 to 291.5) | 222.8 (190.3 to 289.4) |
| Hepatitis B antibody end of SC treatment (N=10,70) | 242.2 (125.5 to 871.9) | 249.2 (225.0 to 289.3) |
Minimal immunoglobulin (IgG) concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and Older
| g/L | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| IgG Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older | 10.1 (9.5 to 10.9) | 10.4 (9.4 to 11.2) |
Immunoglobulin (IgG) Area under the Curve (AUC) AUC/week after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 days for 3-week treatment interval or 28 days for 4-week treatment interval).
| g*days/L | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| IgG Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older | 93.9 (89.1 to 102.1) | 90.5 (83.8 to 98.4) |
Immunoglobulin (IgG) Clearance after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Clearance (CL) is provided after administration of IGIV,10% given via IV route. Apparent Clearance is provided after administration of IGIV, 10% given via SC route with rHuPH20. Clearance and apparent clearance are determined by weight adjusted dose divided by total AUC.
| mL/kg/day | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| IgG Clearance (CL) for Participants Aged 12 Years and Older | 1.4 (1.2 to 1.4) | 1.6 (1.4 to 1.7) |
Maximum immunoglobulin (IgG) concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
| g/L | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| IgG Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older | 21.9 (20.7 to 23.9) | 15.5 (14.5 to 17.1) |
Terminal half life (T1/2) for immunoglobulin (IgG) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Terminal half life is the time it takes for the plasma concentration or the amount of immunoglobulin in the body to be reduced by 50% during the terminal phase
| Days | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| IgG Terminal Half Life (T1/2) for Participants Aged 12 Years and Older | 35.7 (32.4 to 40.4) | 45.3 (41.0 to 60.2) |
Time to Maximum Immunoglobulin (IgG) Concentration (T-max) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
| Days | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| Time to Maximum IgG Concentration (T-max) for Participants Aged 12 Years and Older | 0.1 (0.1 to 0.1) | 5.0 (3.3 to 5.1) |
Minimal tetanus (clostridium tetani toxoid) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
| IU/mL | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| Tetanus Antibody Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older | 2.3 (2.2 to 2.7) | 2.1 (1.9 to 2.4) |
Tetanus (clostridium tetani toxoid) antibody Area under the Curve (AUC) AUC/week after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 days for 3-week treatment interval or 28 days for 4-week treatment interval).
| IU*days/mL | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| Tetanus Antibody Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older | 28.0 (27.0 to 32.2) | 22.6 (19.9 to 25.6) |
Tetanus (clostridium tetani toxoid) antibody Clearance after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Clearance (CL) is provided after administration of IGIV,10% given via IV route. Apparent Clearance is provided after administration of IGIV, 10% given via SC route with rHuPH20. Clearance (CL) and apparent clearance are determined by weight adjusted dose divided by total AUC.
| nL/IU/day | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| Tetanus Antibody Clearance (CL) for Participants Aged 12 Years and Older | 4.5 (3.9 to 5.1) | 5.8 (5.4 to 7.0) |
Terminal half life (T1/2) for tetanus (clostridium tetani toxoid) antibody after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Terminal half life is the time it takes for the plasma concentration or the amount of tetanus antibody in the body to be reduced by 50% during the terminal phase
| Days | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| Tetanus Antibody Terminal Half Life (T1/2) for Participants Aged 12 Years and Older | 22.7 (20.0 to 28.1) | 30.4 (25.7 to 37.2) |
Maximum tetanus (clostridium tetani toxoid) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
| IU/mL | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| Tetanus Antibody Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older | 7.3 (6.8 to 8.1) | 5.0 (4.4 to 5.6) |
Time to Maximum tetanus (clostridium tetani toxoid) antibody Concentration (T-max) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
| Days | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| Time to Maximum Tetanus Antibody Concentration (T-max) for Participants Aged 12 Years and Older | 0.1 (0.1 to 0.2) | 5.1 (4.0 to 6.0) |
Minimal influenza (haemophilus influenzae) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
| μg/mL | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| H. Influenzae Antibody Minimum Plasma Concentration (C_min) for Participants Aged 12 Years and Older | 2.1 (2.0 to 2.6) | 2.2 (1.8 to 2.6) |
Influenza (haemophilus influenzae) antibody Area under the Curve (AUC) AUC/week after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 days for 3-week treatment interval or 28 days for 4-week treatment interval).
| μg*days/mL | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| H. Influenzae Antibody Area Under the Curve (AUC)/Week for Participants Aged 12 Years and Older | 22.4 (21.1 to 26.6) | 22.5 (20.8 to 24.3) |
Influenza (haemophilus influenzae) antibody Clearance after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Clearance (CL) is provided after administration of IGIV,10% given via IV route. Apparent Clearance is provided after administration of IGIV, 10% given via SC route with rHuPH20. Clearance (CL) and apparent clearance are determined by weight adjusted dose divided by total AUC.
| L/kg/day | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| H. Influenzae Antibody Clearance (CL) for Participants Aged 12 Years and Older | 5.8 (5.3 to 6.5) | 6.4 (5.8 to 7.1) |
Maximal influenza (haemophilus influenzae) antibody concentration after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
| μg/mL | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| H. Influenzae Antibody Maximum Plasma Concentration (C_max) for Participants Aged 12 Years and Older | 5.5 (5.1 to 6.8) | 4.1 (3.8 to 4.5) |
Terminal half life (T1/2) for influenza (haemophilus influenzae) antibody after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older. Terminal half life is the time it takes for the plasma concentration or the amount of influenza antibody in the body to be reduced by 50% during the terminal phase.
| Days | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| H. Influenzae Antibody Terminal Half Life (T1/2) for Participants Aged 12 Years and Older | 33.8 (25.6 to 45.3) | 35.0 (32.3 to 41.0) |
Time to Maximum influenza (haemophilus influenzae) antibody Concentration (T-max) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) for participants aged 12 years and older
| Days | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|---|
| Time to Maximum H. Influenzae Antibody Concentration (T-max) for Participants Aged 12 Years and Older | 0.1 (0.1 to 0.2) | 4.8 (3.3 to 5.0) |
Monthly rate of days off school or work after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates were calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month were defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.
| Days off per month | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Rate of Days Off School or Work | 0.23 (0.15 to 0.34) | 0.28 (0.20 to 0.37) |
Monthly rate of days on antibiotics after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates were calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month was defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.
| Days on antibiotics per month | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Rate of Days on Antibiotics | 3.15 (2.19 to 4.35) | 1.69 (1.29 to 2.16) |
Monthly rate of acute physician visits after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates will be calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month will be defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.
| Visits per month | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Rate of Acute Physician Visits | 0.33 (0.23 to 0.45) | 0.40 (0.32 to 0.49) |
Monthly rate of days in hospital after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up. Point estimates and 95% CIs for the monthly rates will be calculated using a Poisson model and the same methodology including allowance for over-dispersion as described for the primary outcome measures. The lengths of the month will be defined as average length of the month in the Gregorian calendar, namely (365\*400+100-3)/(400\*12)= 30.436875 days.
| Days per month | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Rate of Days in Hospital | 0.06 (0.03 to 0.10) | 0.02 (0.01 to 0.03) |
Percentage of participants for which the infusion rate was reduced and/or the infusion interrupted or stopped during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up for tolerability concerns or for adverse events (AEs). An infusion was deemed as tolerated if there are no serious Adverse Drug Reactions (ADR), no non-serious moderate or severe local ADRs that prevent completion of the infusion and no non-serious moderate or severe systemic ADRs during infusion or within 60 minutes of completion of the infusion.
| Percentage of participants | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| % participants with reduced infusion rate only | 6.9 | 9.9 |
| % participants with interrupted infusion rate only | 4.6 | 4.9 |
| % participants with infusion stopped only | 0.0 | 1.2 |
| % participants with no changes to infusion rate | 88.5 | 84.0 |
Percentage of infusions for which the infusion rate was reduced and/or the infusion interrupted or stopped during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up for tolerability concerns or for adverse events (AEs). IV administration of IGIV, 10%: 365 infusions; SC administration of IGIV, 10% with rHuPH20: 1129 infusions
| Percentage of infusions | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| % infusions with infusion rate reduced only | 2.7 | 1.7 |
| % infusions with interrupted infusion rate only | 1.4 | 0.4 |
| % infusions with infusion stopped only | 0.0 | 0.2 |
| % infusions with no changes to infusion rate | 95.9 | 97.7 |
Rate of all AEs (including and excluding infections) per infusion that began during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of an infusion ("temporally associated")
| Number of AEs per infusion | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Including infections | 0.25 (0.20 to 0.50) | 0.21 (0.13 to 0.31) |
| Excluding infections | 0.25 (0.20 to 0.40) | 0.17 (0.09 to 0.26) |
Percentage of participants reporting at least 1 AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")
| Percentage of participants | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Including infections | 66.7 | 86.4 |
| Excluding infections | 63.2 | 82.7 |
Percentage of infusions resulting in at least 1 AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")
| Percentage of infusions | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Including infections | 30.1 | 24.5 |
| Excluding infections | 28.8 | 22.8 |
Percentage of participants reporting at least 1 Moderate or Severe AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")
| Percentage of participants | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 Including Ramp-up |
|---|---|---|
| Including infections | 36.8 | 54.3 |
| Excluding infections | 34.5 | 46.9 |
Percentage of infusions resulting in at least 1 moderate or severe AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion ("temporally associated")
| Percentage of infusions | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Including infections | 0.0 (0.0 to 0.0) | 5.9 (0.0 to 7.1) |
| Excluding infections | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 6.3) |
Percentage of subcutaneous (SC) doses of immune globulin intravenous (IGIV), 10% and recombinant human hyaluronidase (rHuPH20) tolerated at 1 infusion site. An infusion was deemed as tolerated if there were no serious adverse drug reactions (ADRs), no non-serious moderate or severe local ADRs that prevented completion of the infusion, and no non-serious moderate or severe systemic ADRs during or within 60 minutes of completion of the infusion.
| Percentage of infusions | SC Administration of IGIV, 10% With rHuPH20 at Ramp-up | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Percentage of SC Doses of IGIV, 10% and rHuPH20 Tolerated at 1 Infusion Site | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
Percentage of intravenous (IV) and subcutaneous (SC) infusions associated with ≥1 systemic AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via IV or SC route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion
| Percentage of infusions | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Including infections | 25.0 (20.0 to 25.0) | 8.3 (7.7 to 12.5) |
| Excluding infections | 25.0 (16.7 to 25.0) | 8.3 (6.3 to 10.0) |
Percentage of participants with ≥1 systemic AE (including and excluding Infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion
| Percentage of participants | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Including infections | 64.4 | 75.3 |
| Excluding infections | 60.9 | 67.9 |
Percentage of IV and SC (with recombinant human hyaluronidase \[rHuPH20\]) infusions associated with ≥1 local AE (including and excluding infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with rHuPH20 after ramp-up (during infusion) or within 72 hours of completion of infusion
| Percentage of infusions | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Including infections | 0.0 (0.0 to 0.0) | 5.9 (0.0 to 8.3) |
| Excluding infections | 0.0 (0.0 to 0.0) | 5.9 (0.0 to 8.3) |
Percentage of intravenous (IV) and subcutaneous (SC) infusions with recombinant human hyaluronidase (rHuPH20) after ramp-up of immune globulin intravenous (IGIV), 10% associated with ≥1 local AE (including and excluding infections) at any time during the study
| Percentage of infusions | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Including infections | 0.0 (0.0 to 0.0) | 5.9 (0.0 to 8.3) |
| Excluding infections | 0.0 (0.0 to 0.0) | 5.9 (0.0 to 8.3) |
Percentage of participants With ≥1 local AE (including and excluding Infections) during administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up (during infusion) or within 72 hours of completion of infusion
| Percentage of participants | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Including infections | 4.6 | 51.9 |
| Excluding infections | 4.6 | 51.9 |
Percentage of participants With ≥1 local AE (including and excluding infections) after administration of immune globulin intravenous (IGIV), 10% given via intravenous (IV) or subcutaneous (SC) route with recombinant human hyaluronidase (rHuPH20) after ramp-up at any time during the study
| Percentage of participants | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Including infections | 5.7 | 53.1 |
| Excluding infections | 5.7 | 53.1 |
Rate of related AEs defined as the total number of AEs determined by the investigator to be related to the study drug (immune globulin intravenous \[IGIV\], 10% or recombinant human hyaluronidase \[rHuPH20\]), that occur at any time during the study divided by the total number of participants
| Number of AEs per participant | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 Including Ramp-up |
|---|---|---|
| Including infections | 0.00 (0.00 to 0.25) | 0.09 (0.07 to 0.25) |
| Excluding infections | 0.00 (0.00 to 0.25) | 0.09 (0.07 to 0.25) |
Rate of related AEs defined as the total number of AEs determined by the investigator to be related to the study drug (immune globulin intravenous \[IGIV\], 10% or recombinant human hyaluronidase \[rHuPH20\]), that occur at any time during the study divided by the total number of infusions
| Number of AEs per infusion | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Including infections | 0.25 (0.25 to 0.50) | 0.22 (0.13 to 0.31) |
| Excluding infections | 0.25 (0.20 to 0.50) | 0.18 (0.12 to 0.26) |
Frequency of dose corrections based on immune globulin G (IgG) trough levels \<4.5 g/L IgG, if any, for intravenous (IV) (Epoch 1) and subcutaneous with recombinant human hyaluronidase (SC/rHuPH20) after ramp-up (Epoch 2) administration of immune globulin intravenous (IGIV), 10% Defined/calculated as the number of participants requiring dose adjustments divided by the number of participants, for each respective data set.
| Percentage of participants | Study Epoch 1 | Study Epoch 2 |
|---|---|---|
| Frequency of Dose Corrections (If IgG Trough Levels <4.5 g/L) for Each Study Epoch (IV and SC/rHuPH20 Treatment) | 0.0 | 0.0 |
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD-Attention Deficit/Hyperactivity Disorder BP-Blood Pressure COPD- Chronic Obstructive Pulmonary Disease
| Number of AEs | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Abdominal Discomfort-non-SAE, NR, Mod | 0 | 1 |
| Abdominal Distension-non-SAE, Rboth, Mild | 0 | 1 |
| Abdominal Hernia-non-SAE, NR, Mild | 0 | 1 |
| Abdominal Pain-non-SAE, NR, Mild | 1 | 2 |
| Abdominal Pain-non-SAE, NR, Mod | 0 | 1 |
| Abdominal Pain-non-SAE, Rboth, Mild | 0 | 3 |
| Abdominal Pain-non-SAE, Rboth, Mod | 0 | 1 |
| Abdominal Pain Lower-non-SAE, NR, Mild | 0 | 1 |
| Abdominal Pain Upper-non-SAE, NR, Mild | 1 | 5 |
| Abdominal Pain Upper-non-SAE, NR, Mod | 1 | 0 |
| Abdominal Pain Upper-non-SAE, RIGIV, Mild | 0 | 1 |
| Abdominal Pain Upper-non-SAE, RIGIV, Mod | 1 | 0 |
| Abdominal Pain Upper-non-SAE, Rboth, Mild | 0 | 2 |
| Abdominal Tenderness-non-SAE, NR, Mod | 1 | 0 |
| Abdominal Tenderness-non-SAE, RIGIV, Mild | 0 | 1 |
| Abdominal Tenderness-non-SAE, RIGIV, Mod | 0 | 2 |
| Acarodermatitis-non-SAE, NR, Mild | 0 | 1 |
| Acne-non-SAE, NR, Mild | 1 | 1 |
| Acute Sinusitis-non-SAE, NR, Mild | 1 | 0 |
| Acute Sinusitis-non-SAE, NR, Mod | 0 | 4 |
| Adenoidal Hypertrophy-non-SAE, NR, Mod | 0 | 1 |
| Adnexa Uteri Cyst-non-SAE, NR, Mild | 1 | 0 |
| Adrenocortical Insufficiency Acute-SAE, NR, Mod | 0 | 1 |
| Allergic Respiratory Symptom-non-SAE, NR, Mild | 0 | 1 |
| Allergic Sinusitis-non-SAE, NR, Mild | 1 | 0 |
| Alopecia-non-SAE, NR, Mild | 1 | 0 |
| Animal Bite-non-SAE, NR, Mod | 1 | 0 |
| Antibody Test Positive-non-SAE, Rboth, Mod | 0 | 1 |
| Anxiety-non-SAE, NR, Mild | 0 | 1 |
| Anxiety-non-SAE, NR, Mod | 1 | 0 |
| Aphthous Stomatitis-non-SAE, NR, Mild | 2 | 1 |
| Aphthous Stomatitis-non-SAE, NR, Mod | 0 | 1 |
| Arteriosclerosis Coronary Artery-non-SAE, NR, Mild | 0 | 1 |
| Arthralgia-non-SAE, NR, Mild | 0 | 5 |
| Arthralgia-non-SAE, NR, Mod | 1 | 6 |
| Arthralgia-non-SAE, RIGIV, Mild | 0 | 1 |
| Arthralgia-non-SAE, RIGIV, Mod | 0 | 2 |
| Arthritis-non-SAE, NR, Mod | 1 | 1 |
| Arthropathy-non-SAE, NR, Mod | 1 | 0 |
| Arthropod Bite-non-SAE, NR, Mild | 2 | 2 |
| Arthropod Sting-non-SAE, NR, Mild | 0 | 1 |
| Arthropod Sting-non-SAE, NR, Mod | 1 | 0 |
| Aspiration-non-SAE, NR, Mild | 0 | 1 |
| Asthenia-non-SAE, NR, Mild | 0 | 3 |
| Asthenia-non-SAE, NR, Mod | 1 | 0 |
| Asthenia-non-SAE, RIGIV, Mild | 0 | 1 |
| Asthma-non-SAE, NR, Mild | 0 | 4 |
| Asthma-non-SAE, NR, Mod | 8 | 21 |
| Asthma-non-SAE, NR, Severe | 0 | 1 |
| ADHD-non-SAE, NR, Mod | 0 | 1 |
| Back Injury-non-SAE, NR, Mod | 1 | 0 |
| Back Injury-SAE, NR, Severe | 0 | 1 |
| Back Pain-non-SAE, NR, Mild | 1 | 2 |
| Back Pain-non-SAE, NR, Mod | 1 | 5 |
| Bacterial Prostatitis-non-SAE, NR, Mild | 0 | 1 |
| Blepharitis-non-SAE, NR, Mod | 1 | 0 |
| Blister-non-SAE, NR, Mild | 0 | 1 |
| Blood Pressure Decreased-non-SAE, NR, Mild | 0 | 1 |
| Blood Pressure Decreased-non-SAE, Rboth, Mild | 0 | 1 |
| Blood Pressure Increased-non-SAE, NR, Mod | 0 | 1 |
| Blood Pressure Increased-non-SAE, RIGIV, Mild | 0 | 1 |
| Blood Pressure Increased-non-SAE, RIGIV, Mod | 0 | 1 |
| Blood Pressure Increased-non-SAE, RrHu, Mild | 0 | 1 |
| BP Systolic Increased-non-SAE, RIGIV, Mild | 1 | 0 |
| Blood Urea Increased-non-SAE, NR, Mild | 0 | 1 |
| Body Fat Disorder-non-SAE, NR, Mild | 0 | 1 |
| Body Tinea-non-SAE, NR, Mild | 1 | 0 |
| Body Tinea-non-SAE, NR, Mod | 0 | 1 |
| Bone Pain-non-SAE, NR, Mild | 0 | 1 |
| Breast Pain-non-SAE, NR, Mild | 1 | 0 |
| Bronchal Hyperreactivity-non-SAE, NR, Mild | 0 | 1 |
| Bronchitis-non-SAE, NR, Mild | 4 | 2 |
| Bronchitis-non-SAE, NR, Mod | 2 | 8 |
| Bronchitis-SAE, NR, Mod | 1 | 0 |
| Bronchospasm-non-SAE, NR, Mod | 0 | 1 |
| Burn Infection-non-SAE, NR, Mild | 0 | 1 |
| Burning Sensation-non-SAE, RIGIV, Mild | 0 | 1 |
| Burning Sensation-non-SAE, RIGIV, Mod | 0 | 1 |
| Burning Sensation-non-SAE, RrHu, Mild | 0 | 1 |
| Bursitis-non-SAE, NR, Mild | 1 | 0 |
| Bursitis-non-SAE, NR, Mod | 0 | 1 |
| Candidiasis-non-SAE, NR, Mild | 1 | 0 |
| Candidiasis-non-SAE, NR, Mod | 1 | 1 |
| Cardiac Murmur-non-SAE, NR, Mild | 0 | 1 |
| Cellulitis-non-SAE, NR, Mild | 0 | 1 |
| Cellulitis-non-SAE, NR, Mod | 0 | 3 |
| Cellulitis-non-SAE, Rboth, Mod | 0 | 1 |
| Cerumen Impaction-non-SAE, NR, Mild | 0 | 2 |
| Cervical Dysplasia-SAE, NR, Mild | 1 | 1 |
| Cheilitis-non-SAE, NR, Mild | 2 | 0 |
| Chest Pain-non-SAE, NR, Mild | 0 | 2 |
| Chills-non-SAE, NR, Mild | 0 | 3 |
| Chills-non-SAE, RIGIV, Mild | 6 | 1 |
| Chills-non-SAE, RIGIV, Mod | 3 | 0 |
| Chills-non-SAE, Rboth, Mild | 0 | 1 |
| COPD-non-SAE, NR, Mod | 0 | 2 |
| COPD-non-SAE, NR, Severe | 1 | 0 |
| Chronic Sinusitis-non-SAE, NR, Mild | 0 | 4 |
| Chronic Sinusitis-non-SAE, NR, Mod | 1 | 1 |
| Concussion-non-SAE, NR, Mod | 1 | 0 |
| Confusional State-non-SAE, NR, Mod | 0 | 1 |
| Confusional State-non-SAE, RIGIV, Mild | 1 | 0 |
| Conjunctivitis-non-SAE, NR, Mild | 1 | 2 |
| Conjunctivitis Allergic-non-SAE, NR, Mild | 1 | 0 |
| Conjunctivitis Allergic-non-SAE, NR, Mod | 1 | 0 |
| Conjunctivitis Bacterial-non-SAE, NR, Mild | 1 | 1 |
| Conjunctivitis Bacterial-non-SAE, NR, Mod | 0 | 1 |
| Conjunctivitis Bacterial-non-SAE, NR, Severe | 0 | 1 |
| Constipation-non-SAE, NR, Mild | 0 | 3 |
| Contusion-non-SAE, NR, Mild | 1 | 5 |
| Contusion-non-SAE, NR, Mod | 1 | 0 |
| Contusion-non-SAE, RIGIV, Mod | 0 | 1 |
| Coombs Test Positive-non-SAE, RIGIV, Mild | 0 | 1 |
| Costochondritis-non-SAE, NR, Mod | 0 | 1 |
| Cough-non-SAE, NR, Mild | 3 | 6 |
| Cough-non-SAE, NR, Mod | 0 | 2 |
| Cough-non-SAE, RIGIV, Mild | 1 | 0 |
| Cushingoid-non-SAE, NR, Mild | 0 | 1 |
| Cystitis-non-SAE, NR, Mild | 0 | 1 |
| Deafness Neurosensory-non-SAE, NR, Mild | 1 | 0 |
| Decreased Appetite-non-SAE, NR, Mild | 1 | 1 |
| Decreased Appetite-non-SAE, RrHu, Mild | 0 | 1 |
| Decreased Appetite-non-SAE, Rboth, Mild | 0 | 2 |
| Dehydration-non-SAE, NR, Mod | 0 | 2 |
| Dental Caries-non-SAE, NR, Mild | 0 | 2 |
| Dental Caries-non-SAE, NR, Mod | 0 | 3 |
| Depressed Mood-non-SAE, NR, Mild | 0 | 1 |
| Depression-non-SAE, NR, Severe | 0 | 1 |
| Dermal Cyst-non-SAE, NR, Mild | 0 | 1 |
| Dermatitis-non-SAE, NR, Mild | 0 | 2 |
| Dermatitis-non-SAE, NR, Mod | 1 | 0 |
| Dermatitis Acneiform-non-SAE, NR, Mod | 1 | 0 |
| Dermatitis Contact-non-SAE, NR, Mild | 0 | 2 |
| Dermatitis Contact-non-SAE, NR, Mod | 2 | 2 |
| Dermatitis Infected-non-SAE, NR, Mild | 0 | 2 |
| Dermatitis Infected-non-SAE, NR, Mod | 0 | 1 |
| Dermatitis Infected-non-SAE, NR, Severe | 0 | 1 |
| Device Failure-non-SAE, NR, Mild | 2 | 1 |
| Device Failure-non-SAE, NR, Mod | 0 | 2 |
| Diarrhoea-non-SAE, NR, Mild | 3 | 6 |
| Diarrhoea-non-SAE, NR, Mod | 2 | 4 |
| Diarrhoea-non-SAE, RIGIV, Mild | 1 | 1 |
| Diarrhoea-non-SAE, RIGIV, Mod | 1 | 0 |
| Diarrhoea Haemorrhagic-non-SAE, NR, Mild | 1 | 0 |
| Diarrhoea Infectious-non-SAE, NR, Mild | 0 | 1 |
| Diastolic Dysfunction-non-SAE, NR, Mild | 0 | 1 |
| Disaccharide Metabolism Disorder-non-SAE, NR, Mild | 0 | 1 |
| Disturbance in Attention-non-SAE, NR, Mild | 0 | 2 |
| Diverticulitis-non-SAE, NR, Mod | 1 | 0 |
| Dizziness-non-SAE, NR, Mild | 2 | 7 |
| Dizziness-non-SAE, NR, Mod | 0 | 2 |
| Dizziness-non-SAE, RIGIV, Mild | 0 | 3 |
| Dizziness-non-SAE, RIGIV, Mod | 1 | 0 |
| Drug Eruption-non-SAE, NR, Mod | 1 | 0 |
| Dry Eye-non-SAE, NR, Mod | 0 | 1 |
| Dry Mouth-non-SAE, NR, Mild | 0 | 1 |
| Dry Skin-non-SAE, NR, Mild | 0 | 3 |
| Dysmenorrhoea-non-SAE, NR, Mild | 0 | 1 |
| Dyspepsia-non-SAE, NR, Mild | 0 | 2 |
| Dyspepsia-non-SAE, NR, Mod | 0 | 1 |
| Dyspepsia-non-SAE, RIGIV, Mild | 1 | 0 |
| Dysphagia-non-SAE, NR, Mild | 0 | 1 |
| Dysphagia-non-SAE, NR, Mod | 0 | 1 |
| Dyspnoea-non-SAE, NR, Mild | 1 | 0 |
| Dyspnoea-non-SAE, NR, Mod | 1 | 0 |
| Dyspnoea-non-SAE, RIGIV, Mild | 1 | 0 |
| Dysuria-non-SAE, NR, Mild | 0 | 2 |
| Ear Infection-non-SAE, NR, Mild | 2 | 2 |
| Ear Infection-non-SAE, NR, Mod | 1 | 1 |
| Ear Pain-non-SAE, NR, Mild | 3 | 2 |
| Ear Pain-non-SAE, NR, Mod | 0 | 1 |
| Ecchymosis-non-SAE, NR, Mild | 0 | 1 |
| Eczema-non-SAE, NR, Mild | 0 | 1 |
| Eczema-non-SAE, NR, Mod | 0 | 1 |
| Eczema-non-SAE, NR, Severe | 1 | 0 |
| Eosinophil Count-non-SAE, NR, Mild | 0 | 1 |
| Epitaxis-non-SAE, NR, Mild | 2 | 3 |
| Epitaxis-non-SAE, NR, Mod | 2 | 2 |
| Erythema-non-SAE, NR, Mild | 1 | 0 |
| Erythema-non-SAE, RIGIV, Mod | 0 | 1 |
| Erythema-non-SAE, RrHu, Mild | 0 | 1 |
| Erythema-non-SAE, Rboth, Mild | 0 | 1 |
| Erythema-non-SAE, Rboth, Mod | 0 | 1 |
| Eustachian Tube Dysfunction-non-SAE, NR, Mild | 1 | 0 |
| Excoriation-non-SAE, NR, Mild | 2 | 2 |
| Extravasation Blood-non-SAE, Rboth, Mild | 0 | 1 |
| Eye Irritation-non-SAE, NR, Mild | 0 | 1 |
| Eye Pruritus-non-SAE, NR, Mod | 0 | 1 |
| Eye Swelling-non-SAE, NR, Mod | 0 | 1 |
| Fall-non-SAE, NR, Mild | 0 | 1 |
| Fall-non-SAE, NR, Mod | 0 | 1 |
| Fatigue-non-SAE, NR, Mild | 1 | 5 |
| Fatigue-non-SAE, NR, Mod | 1 | 2 |
| Fatigue-non-SAE, RIGIV, Mild | 8 | 8 |
| Fatigue-non-SAE, RIGIV, Mod | 0 | 3 |
| Fatigue-non-SAE, Rboth, Mild | 0 | 3 |
| Feeling Abnormal-non-SAE, Rboth, Mod | 0 | 1 |
| Feeling Cold-non-SAE, RIGIV, Mild | 2 | 0 |
| Flatulence-non-SAE, NR, Mild | 0 | 1 |
| Flatulence-non-SAE, NR, Mod | 0 | 1 |
| Food Poisoning-non-SAE, NR, Mod | 0 | 1 |
| Free Haemoglobin Present-non-SAE, NR, Mild | 1 | 1 |
| Free Haemoglobin Present-non-SAE, NR, Severe | 1 | 0 |
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe
| Number of AEs | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Gait Disturbance-non-SAE, NR, Mild | 0 | 1 |
| Gastroenteritis-non-SAE, NR, Mild | 0 | 3 |
| Gastroenteritis-non-SAE, NR, Mod | 2 | 2 |
| Gastroenteritis-non-SAE, RIGIV, Mild | 1 | 0 |
| Gastroenteritis-SAE, NR, Mod | 0 | 1 |
| Gastroenteritis Bacterial-non-SAE, NR, Mod | 0 | 1 |
| Gastroenteritis Viral-non-SAE, NR, Mild | 3 | 6 |
| Gastroenteritis Viral-non-SAE, NR, Mod | 0 | 5 |
| Gastroenteritis Viral-non-SAE, RIGIV, Mild | 0 | 1 |
| Gastrointestinal Haemorrhage-non-SAE, NR, Severe | 0 | 1 |
| Gastrooesophageal Reflux Disease-non-SAE, NR, Mild | 1 | 2 |
| Gastrooesophageal Reflux Disease-non-SAE, NR, Mod | 1 | 0 |
| Genital Herpes-non-SAE, NR, Mild | 1 | 0 |
| Genital Swelling-non-SAE, Rboth, Mod | 0 | 1 |
| Goitre-non-SAE, NR, Mild | 1 | 0 |
| Gout-non-SAE, NR, Mild | 0 | 1 |
| Grand Mal Convulsion-non-SAE, NR, Severe | 1 | 0 |
| Grand Mal Convulsion-SAE, NR, Severe | 0 | 1 |
| Gravitational Oedema-non-SAE, Rboth, Mod | 0 | 1 |
| Groin Pain-non-SAE, NR, Mild | 0 | 1 |
| Groin Pain-non-SAE, RIGIV, Mild | 0 | 1 |
| Groin Pain-non-SAE, RrHu, Mod | 0 | 1 |
| Haematoma-non-SAE, NR, Mild | 1 | 1 |
| Haematoma-non-SAE, NR, Mod | 0 | 1 |
| Haematuria-non-SAE, NR, Mild | 0 | 1 |
| Haemoglobin Abnormal-non-SAE, NR, Mild | 0 | 1 |
| Haemorrhoids-non-SAE, NR, Mild | 0 | 2 |
| Hand Fracture-non-SAE, NR, Mod | 0 | 1 |
| Headache-non-SAE, NR, Mild | 13 | 16 |
| Headache-non-SAE, NR, Mod | 1 | 3 |
| Headache-non-SAE, NR, Severe | 1 | 0 |
| Headache-non-SAE, RIGIV, Mild | 25 | 14 |
| Headache-non-SAE, RIGIV, Mod | 12 | 5 |
| Headache-non-SAE, RIGIV, Severe | 1 | 0 |
| Headache-non-SAE, Rboth, Mild | 0 | 9 |
| Headache-non-SAE, Rboth, Mod | 0 | 8 |
| Headache-SAE, NR, Severe | 0 | 1 |
| Hearing Impaired-non-SAE, NR, Mild | 0 | 1 |
| Heart Rate Increased-non-SAE, RIGIV, Mild | 4 | 0 |
| Heat Rash-non-SAE, NR, Mild | 0 | 1 |
| Heat Stroke-non-SAE, NR, Mod | 0 | 1 |
| Herpes Simplex Ophthalmic-non-SAE, NR, Mod | 0 | 1 |
| Herpes Zoster-non-SAE, NR, Mod | 0 | 1 |
| Hiatus Hernia-non-SAE, NR, Mod | 0 | 1 |
| Hot Flush-non-SAE, RIGIV, Mild | 1 | 0 |
| Hyperaesthesia-non-SAE, NR, Mild | 0 | 1 |
| Hypercholesterolaemia-non-SAE, NR, Mod | 0 | 1 |
| Hyperkeratosis-non-SAE, NR, Mild | 0 | 1 |
| Hypertension-non-SAE, NR, Mod | 0 | 4 |
| Hypertension-non-SAE, RIGIV, Mild | 0 | 2 |
| Hypertension-non-SAE, RIGIV, Mod | 0 | 1 |
| Hypertonia-non-SAE, NR, Mild | 0 | 1 |
| Hypothyroidism-non-SAE, NR, Mild | 0 | 1 |
| Idiopathic Urticaria-non-SAE, NR, Mod | 1 | 0 |
| Increased Upper Airway Secretion-non-SAE, NR, Mild | 2 | 0 |
| Infected Bites-non-SAE, NR, Mild | 0 | 2 |
| Infected Bites-non-SAE, NR, Mod | 1 | 1 |
| Infection-non-SAE, NR, Mod | 0 | 2 |
| Influenza-non-SAE, NR, Mild | 1 | 2 |
| Influenza-non-SAE, NR, Mod | 4 | 3 |
| Influenza Like Illness-non-SAE, NR, Mild | 0 | 1 |
| Infusion Related Reaction-non-SAE, RIGIV, Mild | 0 | 1 |
| Infusion Related Reaction-non-SAE, RIGIV, Mod | 1 | 0 |
| Infusion Related Reaction-non-SAE, Rboth, Mild | 0 | 1 |
| Infusion Related Reaction-non-SAE, Rboth, Mod | 0 | 1 |
| Infusion Site Discomfort-non-SAE, RIGIV, Mild | 0 | 6 |
| Infusion Site Discomfort-non-SAE, RrHu, Mod | 0 | 1 |
| Infusion Site Discomfort-non-SAE, Rboth, Mild | 0 | 15 |
| Infusion Site Discomfort-non-SAE, Rboth, Mod | 0 | 8 |
| Infusion Site Erythema-non-SAE, RIGIV, Mild | 0 | 1 |
| Infusion Site Erythema-non-SAE, RrHu, Mild | 0 | 2 |
| Infusion Site Erythema-non-SAE, Rboth, Mild | 0 | 20 |
| Infusion Site Erythema-non-SAE, Rboth, Mod | 0 | 5 |
| Infusion Site Extravasation-non-SAE, NR, Mild | 2 | 0 |
| Infusion Site Haematoma-non-SAE, RIGIV, Mild | 0 | 1 |
| Infusion Site Haemorrhage-non-SAE, Rboth, Mild | 0 | 1 |
| Infusion Site Hypersensitivity-non-SAE, NR, Severe | 0 | 1 |
| Infusion Site Hypersensitivity-non-SAE, Rboth, Mod | 0 | 1 |
| Infusion Site Mass-non-SAE, RIGIV, Mild | 0 | 1 |
| Infusion Site Mass-non-SAE, Rboth, Mild | 0 | 2 |
| Infusion Site Oedema-non-SAE, Rboth, Mild | 0 | 4 |
| Infusion Site Oedema-non-SAE, Rboth, Mod | 0 | 5 |
| Infusion Site Pain-non-SAE, NR, Mild | 0 | 2 |
| Infusion Site Pain-non-SAE, RIGIV, Mild | 1 | 12 |
| Infusion Site Pain-non-SAE, RIGIV, Mod | 0 | 6 |
| Infusion Site Pain-non-SAE, RrHu, Mild | 0 | 35 |
| Infusion Site Pain-non-SAE, RrHu, Mod | 0 | 1 |
| Infusion Site Pain-non-SAE, Rboth, Mild | 0 | 19 |
| Infusion Site Pain-non-SAE, Rboth, Mod | 0 | 16 |
| Infusion Site Pain-non-SAE, Rboth, Severe | 0 | 1 |
| Infusion Site Pruritus-non-SAE, RIGIV, Mild | 0 | 2 |
| Infusion Site Pruritus-non-SAE, RrHu, Mild | 0 | 5 |
| Infusion Site Pruritus-non-SAE, Rboth, Mild | 0 | 6 |
| Infusion Site Pruritus-non-SAE, Rboth, Mod | 0 | 4 |
| Infusion Site Reaction-non-SAE, Rboth, Mild | 0 | 1 |
| Infusion Site Reaction-non-SAE, Rboth, Mod | 0 | 2 |
| Infusion Site Swelling-non-SAE, RIGIV, Mild | 0 | 2 |
| Infusion Site Swelling-non-SAE, Rboth, Mild | 0 | 3 |
| Infusion Site Swelling-non-SAE, Rboth, Mod | 0 | 4 |
| Infusion Site Swelling-non-SAE, Rboth, Severe | 0 | 1 |
| Infusion Site Warmth-non-SAE, Rboth, Mild | 0 | 2 |
| Ingrowing Nail-non-SAE, NR, Mod | 0 | 1 |
| Injection Site Erythema-non-SAE, RIGIV, Mild | 0 | 1 |
| Injury-non-SAE, NR, Mild | 1 | 0 |
| Insomnia-non-SAE, NR, Mild | 1 | 0 |
| Intervertebral Disc Protrusion-non-SAE, NR, Mod | 1 | 0 |
| Irritable Bowel Syndrome-non-SAE, NR, Mild | 0 | 1 |
| Irritable Bowel Syndrome-non-SAE, NR, Mod | 0 | 2 |
| Joint Effusion-non-SAE, NR, Mild | 0 | 1 |
| Joint Effusion-non-SAE, NR, Mod | 0 | 1 |
| Joint Injury-non-SAE, NR, Mod | 1 | 1 |
| Joint Range of Motion Decreased-non-SAE, NR, Mod | 0 | 2 |
| Joint Sprain-non-SAE, NR, Mild | 0 | 1 |
| Joint Sprain-non-SAE, NR, Mod | 0 | 2 |
| Joint Swelling-non-SAE, NR, Mild | 0 | 1 |
| Jugular Vein Distension-non-SAE, NR, Mild | 0 | 1 |
| Lethargy-non-SAE, NR, Mild | 0 | 1 |
| Lethargy-non-SAE, RIGIV, Mod | 1 | 0 |
| Ligament Injury-non-SAE, NR, Mod | 0 | 1 |
| Ligament Sprain-non-SAE, NR, Mod | 0 | 1 |
| Limb Injury-non-SAE, NR, Mild | 1 | 0 |
| Lip Injury-non-SAE, NR, Mild | 0 | 1 |
| Lip Ulceration-non-SAE, NR, Mild | 0 | 1 |
| Local Swelling-non-SAE, RIGIV, Mild | 0 | 3 |
| Local Swelling-non-SAE, Rboth, Mild | 0 | 3 |
| Localised Infection-non-SAE, NR, Mild | 0 | 1 |
| Localised Oedema-non-SAE, RIGIV, Mild | 0 | 1 |
| Localised Oedema-non-SAE, Rboth, Mod | 0 | 1 |
| Lung Infection-non-SAE, NR, Mod | 1 | 0 |
| Lung Infection-non-SAE, NR, Severe | 1 | 0 |
| Lymph Gland Infection-non-SAE, NR, Mod | 1 | 0 |
| Lymph Node Pain-non-SAE, NR, Mild | 1 | 0 |
| Lymph Node Pain-non-SAE, NR, Mod | 0 | 1 |
| Lymph Node Palpable-non-SAE, NR, Mild | 1 | 0 |
| Lymphadenitis-non-SAE, NR, Mod | 1 | 0 |
| Lymphadenopathy-non-SAE, NR, Mild | 2 | 8 |
| Lymphangitis-non-SAE, NR, Mod | 0 | 1 |
| Lymphocyte Count Decreased-non-SAE, RIGIV, Mild | 0 | 1 |
| Lymphoedema-non-SAE, NR, Severe | 1 | 0 |
| Malaise-non-SAE, NR, Mild | 0 | 2 |
| Malaise-non-SAE, NR, Mod | 0 | 1 |
| Malaise-non-SAE, RIGIV, Mod | 1 | 0 |
| Malaise-non-SAE, RrHu, Mild | 0 | 1 |
| Malaise-non-SAE, RrHu, Mod | 0 | 1 |
| Memory Impairment-non-SAE, NR, Mod | 0 | 1 |
| Migraine-non-SAE, NR, Mild | 1 | 1 |
| Migraine-non-SAE, NR, Mod | 0 | 2 |
| Migraine-non-SAE, NR, Severe | 1 | 0 |
| Migraine-non-SAE, RIGIV, Mild | 1 | 1 |
| Migraine-non-SAE, RIGIV, Mod | 1 | 4 |
| Migraine-non-SAE, RIGIV, Severe | 0 | 1 |
| Migraine-non-SAE, Rboth, Mod | 0 | 1 |
| Molluscum Contagiosum-non-SAE, NR, Mild | 2 | 0 |
| Mouth Ulceration-non-SAE, NR, Mild | 1 | 0 |
| Multiple Sclerosis Relapse-non-SAE, NR, Mod | 0 | 1 |
| Muscle Fatigue-non-SAE, NR, Mild | 0 | 1 |
| Muscle Injury-non-SAE, NR, Mild | 0 | 2 |
| Muscle Spasms-non-SAE, NR, Mild | 0 | 1 |
| Muscle Spasms-non-SAE, RIGIV, Mild | 1 | 0 |
| Muscle Strain-non-SAE, NR, Mild | 1 | 1 |
| Muscle Strain-non-SAE, NR, Mod | 0 | 1 |
| Muscular Weakness-non-SAE, NR, Mild | 1 | 0 |
| Musculoskeletal Chest Pain-non-SAE, NR, Mild | 0 | 1 |
| Musculoskeletal Chest Pain-non-SAE, RIGIV, Mild | 0 | 1 |
| Musculoskeletal Pain-non-SAE, NR, Mild | 2 | 0 |
| Musculoskeletal Pain-non-SAE, NR, Mod | 1 | 1 |
| Musculoskeletal Stiffness-non-SAE, NR, Mild | 1 | 1 |
| Myalgia-non-SAE, NR, Mild | 3 | 5 |
| Myalgia-non-SAE, NR, Mod | 1 | 4 |
| Myalgia-non-SAE, NR, Severe | 0 | 1 |
| Myalgia-non-SAE, RIGIV, Mild | 0 | 6 |
| Myalgia-non-SAE, RIGIV, Mod | 1 | 1 |
| Myalgia-non-SAE, Rboth, Mild | 0 | 3 |
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Resp.-Respiratory WBC - White blood cells
| Number of AEs | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Nasal Congestion-non-SAE, NR, Mild | 4 | 3 |
| Nasal Congestion-non-SAE, NR, Mod | 0 | 2 |
| Nasal Congestion-non-SAE, RIGIV, Mild | 0 | 3 |
| Nasal Discomfort-non-SAE, NR, Mild | 0 | 1 |
| Nasal Mucosal Discolouration-non-SAE, NR, Mild | 0 | 1 |
| Nasal Turbinate Hypertrophy-non-SAE, NR, Mild | 0 | 1 |
| Nasopharyngitis-non-SAE, NR, Mild | 4 | 8 |
| Nausea-non-SAE, NR, Mild | 3 | 17 |
| Nausea-non-SAE, NR, Mod | 2 | 3 |
| Nausea-non-SAE, RIGIV, Mild | 7 | 1 |
| Nausea-non-SAE, RIGIV, Mod | 1 | 0 |
| Nausea-non-SAE, Rboth, Mild | 0 | 4 |
| Neck Pain-non-SAE, NR, Mild | 1 | 1 |
| Night Sweats-non-SAE, NR, Mild | 1 | 0 |
| Night Sweats-non-SAE, NR, Mod | 0 | 1 |
| Nodule-non-SAE, Rboth, Mild | 0 | 2 |
| Oedema-non-SAE, RIGIV, Mild | 0 | 1 |
| Oedema Genital-non-SAE, Rboth, Severe | 0 | 1 |
| Oedema Peripheral-non-SAE, NR, Mild | 0 | 1 |
| Oedema Peripheral-non-SAE, NR, Mod | 0 | 1 |
| Oedema Peripheral-non-SAE, Rboth, Mod | 0 | 2 |
| Oesophagitis-non-SAE, NR, Mild | 0 | 1 |
| Onychomycosis-non-SAE, NR, Mild | 0 | 1 |
| Oral Candidiasis-non-SAE, NR, Mod | 0 | 1 |
| Oral Fungal Infection-non-SAE, NR, Mild | 0 | 1 |
| Oral Herpes-non-SAE, NR, Mild | 1 | 2 |
| Oral Herpes-non-SAE, NR, Mod | 0 | 1 |
| Oral Pain-non-SAE, NR, Mild | 0 | 1 |
| Oral Pain-non-SAE, RrHu, Severe | 0 | 1 |
| Oropharyngeal Pain-non-SAE, NR, Mild | 1 | 4 |
| Oropharyngeal Pain-non-SAE, NR, Mod | 2 | 1 |
| Osteoarthritis-non-SAE, NR, Mod | 0 | 1 |
| Osteopenia-non-SAE, NR, Mild | 0 | 1 |
| Osteopenia-non-SAE, NR, Mod | 0 | 1 |
| Osteoporosis-non-SAE, NR, Mild | 0 | 1 |
| Otitis Externa-non-SAE, NR, Mild | 0 | 1 |
| Otitis Externa-non-SAE, NR, Mod | 0 | 1 |
| Otitis Media-non-SAE, NR, Mod | 1 | 1 |
| Pain-non-SAE, NR, Mild | 1 | 5 |
| Pain-non-SAE, NR, Mod | 1 | 1 |
| Pain-non-SAE, RIGIV, Mild | 0 | 1 |
| Pain-non-SAE, RIGIV, Mod | 2 | 1 |
| Pain-non-SAE, Rboth, Mild | 0 | 1 |
| Pain-non-SAE, Rboth, Mod | 0 | 1 |
| Pain in Extremity-non-SAE, NR, Mild | 2 | 1 |
| Pain in Extremity-non-SAE, NR, Mod | 1 | 2 |
| Pain in Extremity-non-SAE, RIGIV, Mod | 2 | 0 |
| Pain in Extremity-non-SAE, RIGIV, Severe | 1 | 0 |
| Pain in Extremity-non-SAE, Rboth, Mild | 0 | 3 |
| Pain in Extremity-non-SAE, Rboth, Mod | 0 | 2 |
| Palpitations-non-SAE, NR, Mild | 1 | 1 |
| Papule-non-SAE, NR, Mild | 0 | 1 |
| Peptic Ulcer Haemorrhage-SAE, NR, Severe | 1 | 0 |
| Periorbital Haematoma-non-SAE, NR, Mild | 0 | 1 |
| Peripheral Nerve Injury-non-SAE, NR, Mild | 0 | 1 |
| Pertussis-non-SAE, NR, Mod | 0 | 1 |
| Petit Mal Epilepsy-SAE, NR, Severe | 0 | 1 |
| Pharyngeal Erythema-non-SAE, NR, Mild | 1 | 3 |
| Pharyngitis-non-SAE, NR, Mild | 1 | 4 |
| Pharyngitis-non-SAE, NR, Mod | 1 | 0 |
| Pharyngitis Streptococcal-non-SAE, NR, Mod | 0 | 4 |
| Pneumonia-non-SAE, NR, Mild | 0 | 1 |
| Pneumonia-non-SAE, NR, Mod | 0 | 1 |
| Pneumonia Bacterial-non-SAE, NR, Mod | 0 | 1 |
| Post Procedural Infection-non-SAE, NR, Mild | 1 | 2 |
| Post Procedural Infection-non-SAE, NR, Mod | 0 | 5 |
| Postictal Paralysis-non-SAE, NR, Mod | 0 | 1 |
| Postoperative Wound Infection-non-SAE, NR, Mod | 0 | 1 |
| Procedural Pain-non-SAE, NR, Mild | 0 | 2 |
| Procedural Pain-non-SAE, NR, Mod | 0 | 1 |
| Productive Cough-non-SAE, NR, Mild | 1 | 1 |
| Pruritus-non-SAE, NR, Mild | 1 | 0 |
| Pruritus-non-SAE, RIGIV, Mild | 1 | 0 |
| Pruritus-non-SAE, Rboth, Mild | 0 | 1 |
| Pruritus-non-SAE, Rboth, Mod | 0 | 1 |
| Pruritus Generalized-non-SAE, NR, Mild | 1 | 0 |
| Pseudomonas Infection-non-SAE, NR, Mod | 0 | 1 |
| Psoriasis-non-SAE, NR, Mod | 0 | 1 |
| Pyrexia-non-SAE, NR, Mild | 3 | 11 |
| Pyrexia-non-SAE, NR, Mod | 2 | 1 |
| Pyrexia-non-SAE, RIGIV, Mild | 4 | 6 |
| Pyrexia-non-SAE, RIGIV, Mod | 2 | 2 |
| Pyrexia-non-SAE, Rboth, Mild | 0 | 2 |
| Rales-non-SAE, NR, Mild | 0 | 1 |
| Rales-non-SAE, NR, Mod | 0 | 1 |
| Rash-non-SAE, NR, Mild | 2 | 5 |
| Rash-non-SAE, NR, Mod | 0 | 1 |
| Rash Erythematous-non-SAE, NR, Mild | 0 | 1 |
| Rash Macro-Papular-non-SAE, Rboth, Mild | 0 | 1 |
| Rash Pustular-non-SAE, NR, Mild | 0 | 1 |
| Rash Pustular-non-SAE, NR, Mod | 1 | 0 |
| Rash Papular-non-SAE, NR, Mild | 0 | 1 |
| Respiratory Failure-SAE, NR, Severe | 0 | 1 |
| Respiratory Rate Increased-non-SAE, NR, Mild | 0 | 1 |
| Respiratory Tract Congestion-non-SAE, NR, Mild | 0 | 1 |
| Respiratory Tract Infection-non-SAE, NR, Mild | 1 | 1 |
| Respiratory Tract Infection-non-SAE, NR, Mod | 1 | 3 |
| Respiratory Tract Infection Viral-non-SAE, NR, Mod | 1 | 0 |
| Rhinitis Allergic-non-SAE, NR, Mild | 1 | 3 |
| Rhinitis Allergic-non-SAE, NR, Mod | 3 | 1 |
| Rhinitis Allergic-non-SAE, RIGIV, Mod | 1 | 0 |
| Rhinorrhoea-non-SAE, NR, Mild | 1 | 1 |
| Road Traffic Accident-non-SAE, NR, Mod | 0 | 2 |
| Scleritis-non-SAE, NR, Mild | 1 | 1 |
| Scleritis-non-SAE, NR, Mod | 0 | 1 |
| Scratch-non-SAE, NR, Mild | 1 | 0 |
| Seborrhoeic Dermatitis-non-SAE, NR, Mild | 0 | 1 |
| Sicca Syndrome-non-SAE, NR, Mod | 0 | 1 |
| Sinus Congestion-non-SAE, NR, Mild | 1 | 0 |
| Sinus Headache-non-SAE, NR, Mild | 1 | 0 |
| Sinusitis-non-SAE, NR, Mild | 6 | 25 |
| Sinusitis-non-SAE, NR, Mod | 13 | 26 |
| Sinusitis-non-SAE, NR, Severe | 0 | 1 |
| Sinusitis-non-SAE, RIGIV, Mod | 0 | 1 |
| Skeletal Injury-non-SAE, NR, Mild | 0 | 1 |
| Skeletal Injury-non-SAE, NR, Mod | 0 | 1 |
| Skin Hyperpigmentation-non-SAE, Rboth, Mild | 0 | 1 |
| Skin Laceration-non-SAE, NR, Mild | 0 | 1 |
| Skin Laceration-non-SAE, NR, Mod | 0 | 1 |
| Skin Lesion-non-SAE, NR, Mild | 2 | 1 |
| Skin Lesion-non-SAE, NR, Mod | 1 | 0 |
| Skin Lesion-non-SAE, RIGIV, Mild | 0 | 2 |
| Skin Papilloma-non-SAE, NR, Mod | 1 | 0 |
| Spinal Osteoarthritis-non-SAE, NR, Mild | 0 | 2 |
| Squamous Cell Carcinoma-non-SAE, NR, Mod | 1 | 1 |
| Status Epilepticus-SAE, NR, Severe | 0 | 1 |
| Suicidal Ideation-non-SAE, NR, Mild | 1 | 0 |
| Sunburn-non-SAE, NR, Mild | 0 | 1 |
| Swelling-non-SAE, Rboth, Mild | 0 | 1 |
| Swelling-non-SAE, Rboth, Mod | 0 | 3 |
| Syncope-non-SAE, NR, Mild | 0 | 1 |
| Tachycardia-non-SAE, NR, Mild | 0 | 3 |
| Tachycardia-non-SAE, NR, Mod | 0 | 1 |
| Therapy Cessation-non-SAE, NR, Severe | 0 | 1 |
| Thrombosis-non-SAE, NR, Severe | 0 | 1 |
| Thrombosis-SAE, NR, Mod | 0 | 1 |
| Tinea Infection-non-SAE, NR, Mild | 2 | 0 |
| Tongue Coated-non-SAE, NR, Mild | 0 | 1 |
| Tonsillar Hypertrophy-non-SAE, NR, Mod | 0 | 1 |
| Tonsillar Hypertrophy-SAE, NR, Mild | 0 | 1 |
| Tooth Abscess-non-SAE, NR, Mild | 1 | 0 |
| Tooth Abscess-non-SAE, NR, Mod | 0 | 1 |
| Tooth Impacted-non-SAE, NR, Mod | 0 | 1 |
| Tooth Infection-non-SAE, NR, Mod | 0 | 1 |
| Toothache-non-SAE, NR, Mod | 0 | 1 |
| Tongue Injury-non-SAE, NR, Mild | 0 | 1 |
| Tremor-non-SAE, NR, Mild | 0 | 1 |
| Tricuspid Valve Incompetence-non-SAE, NR, Mild | 0 | 1 |
| Tympanic Membrane Disorder-non-SAE, NR, Mild | 1 | 0 |
| Tympanic Membrane Hyperaemia-non-SAE, NR, Mild | 0 | 2 |
| Upper Airway Cough Syndrome-non-SAE, NR, Mild | 0 | 1 |
| Upper Resp. Tract Infection-non-SAE, NR, Mild | 7 | 34 |
| Upper Resp. Tract Infection-non-SAE, NR, Mod | 2 | 10 |
| Urinary Tract Infection-non-SAE, NR, Mild | 1 | 2 |
| Urinary Tract Infection-non-SAE, NR, Mod | 5 | 4 |
| Urine Analysis Abnormal-non-SAE, NR, Mild | 0 | 1 |
| Urticaria-non-SAE, NR, Mild | 0 | 5 |
| Urticaria-non-SAE, NR, Mod | 0 | 1 |
| Urticaria-non-SAE, RIGIV, Mild | 1 | 0 |
| Uterine Polyp-non-SAE, NR, Mod | 0 | 1 |
| Vaginal Haemorrhage-non-SAE, NR, Mod | 0 | 1 |
| Vascular Access Complication-non-SAE, NR, Mild | 1 | 0 |
| Vertigo-non-SAE, NR, Mod | 0 | 1 |
| Viral Diarrhoea-non-SAE, NR, Mild | 0 | 1 |
| Viral Infection-non-SAE, NR, Mild | 3 | 7 |
| Viral Infection-non-SAE, NR, Mod | 3 | 3 |
| Viral Infection-SAE, NR, Mild | 1 | 0 |
| Viral Upper Resp. Tract Infection-non-SAE, NR Mild | 1 | 8 |
| Viral Upper Resp. Tract Infection-non-SAE, NR, Mod | 1 | 1 |
| Vision Blurred-non-SAE, NR, Mild | 0 | 1 |
| Vitamin D Deficiency-non-SAE, NR, Mild | 1 | 0 |
| Vitamin D Deficiency-non-SAE, NR, Mod | 0 | 2 |
| Vomiting-non-SAE, NR, Mild | 5 | 7 |
| Vomiting-non-SAE, NR, Mod | 0 | 3 |
| Vomiting-non-SAE, RIGIV, Mild | 4 | 3 |
| Vomiting-non-SAE, RIGIV, Mod | 1 | 4 |
| Vomiting-non-SAE, RIGIV, Severe | 1 | 0 |
| Vomiting-non-SAE, Rboth, Mod | 0 | 1 |
| Vulvovaginal Pruritus-non-SAE, RIGIV, Mild | 0 | 1 |
| Weight Decreased-non-SAE, RrHu, Mild | 0 | 1 |
| Weight Decreased-non-SAE, RrHu, Mod | 0 | 1 |
| Wheezing-non-SAE, NR, Mod | 0 | 1 |
| WBC Count Decreased-non-SAE, RIGIV, Mild | 0 | 1 |
| White Blood Cells Urine Positive-non-SAE, NR, Mild | 0 | 1 |
| WBC Urine Positive-non-SAE, RIGIV Mild | 1 | 0 |
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD-Attention Deficit/Hyperactivity Disorder BP-Blood Pressure COPD- Chronic Obstructive Pulmonary Disease
| Number of AEs per infusion | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Abdominal Discomfort-non-SAE, NR, Mod | 0 | 0.001 |
| Abdominal Distension-non-SAE, Rboth, Mild | 0 | 0.001 |
| Abdominal Hernia-non-SAE, NR, Mild | 0 | 0.001 |
| Abdominal Pain-non-SAE, NR, Mild | 0.003 | 0.002 |
| Abdominal Pain-non-SAE, NR, Mod | 0 | 0.001 |
| Abdominal Pain-non-SAE, Rboth, Mild | 0 | 0.003 |
| Abdominal Pain-non-SAE, Rboth, Mod | 0 | 0.001 |
| Abdominal Pain Lower-non-SAE, NR, Mild | 0 | 0.001 |
| Abdominal Pain Upper-non-SAE, NR, Mild | 0.003 | 0.004 |
| Abdominal Pain Upper-non-SAE, NR, Mod | 0.003 | 0 |
| Abdominal Pain Upper-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Abdominal Pain Upper-non-SAE, RIGIV, Mod | 0.003 | 0 |
| Abdominal Pain Upper-non-SAE, Rboth, Mild | 0 | 0.002 |
| Abdominal Tenderness-non-SAE, NR, Mod | 0.003 | 0 |
| Abdominal Tenderness-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Abdominal Tenderness-non-SAE, RIGIV, Mod | 0 | 0.002 |
| Acarodermatitis-non-SAE, NR, Mild | 0 | 0.001 |
| Acne-non-SAE, NR, Mild | 0.003 | 0.001 |
| Acute Sinusitis-non-SAE, NR, Mild | 0.003 | 0 |
| Acute Sinusitis-non-SAE, NR, Mod | 0 | 0.004 |
| Adenoidal Hypertrophy-non-SAE, NR, Mod | 0 | 0.001 |
| Adnexa Uteri Cyst-non-SAE, NR, Mild | 0.003 | 0 |
| Adrenocortical Insufficiency Acute-SAE, NR, Mod | 0 | 0.001 |
| Allergic Respiratory Symptom-non-SAE, NR, Mild | 0 | 0.001 |
| Allergic Sinusitis-non-SAE, NR, Mild | 0.003 | 0 |
| Alopecia-non-SAE, NR, Mild | 0.003 | 0 |
| Animal Bite-non-SAE, NR, Mod | 0.003 | 0 |
| Antibody Test Positive-non-SAE, Rboth, Mod | 0 | 0.001 |
| Anxiety-non-SAE, NR, Mild | 0 | 0.001 |
| Anxiety-non-SAE, NR, Mod | 0.003 | 0 |
| Aphthous Stomatitis-non-SAE, NR, Mild | 0.005 | 0.001 |
| Aphthous Stomatitis-non-SAE, NR, Mod | 0 | 0.001 |
| Arteriosclerosis Coronary Artery-non-SAE, NR, Mild | 0 | 0.001 |
| Arthralgia-non-SAE, NR, Mild | 0 | 0.004 |
| Arthralgia-non-SAE, NR, Mod | 0.003 | 0.005 |
| Arthralgia-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Arthralgia-non-SAE, RIGIV, Mod | 0 | 0.002 |
| Arthritis-non-SAE, NR, Mod | 0.003 | 0.001 |
| Arthropathy-non-SAE, NR, Mod | 0.003 | 0 |
| Arthropod Bite-non-SAE, NR, Mild | 0.005 | 0.002 |
| Arthropod Sting-non-SAE, NR, Mild | 0 | 0.001 |
| Arthropod Sting-non-SAE, NR, Mod | 0.003 | 0 |
| Aspiration-non-SAE, NR, Mild | 0 | 0.001 |
| Asthenia-non-SAE, NR, Mild | 0 | 0.003 |
| Asthenia-non-SAE, NR, Mod | 0.003 | 0 |
| Asthenia-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Asthma-non-SAE, NR, Mild | 0 | 0.004 |
| Asthma-non-SAE, NR, Mod | 0.022 | 0.019 |
| Asthma-non-SAE, NR, Severe | 0 | 0.001 |
| ADHD-non-SAE, NR, Mod | 0 | 0.001 |
| Back Injury-non-SAE, NR, Mod | 0.003 | 0 |
| Back Injury-SAE, NR, Severe | 0 | 0.001 |
| Back Pain-non-SAE, NR, Mild | 0.003 | 0.002 |
| Back Pain-non-SAE, NR, Mod | 0.003 | 0.004 |
| Bacterial Prostatitis-non-SAE, NR, Mild | 0 | 0.001 |
| Blepharitis-non-SAE, NR, Mod | 0.003 | 0 |
| Blister-non-SAE, NR, Mild | 0 | 0.001 |
| Blood Pressure Decreased-non-SAE, NR, Mild | 0 | 0.001 |
| Blood Pressure Decreased-non-SAE, Rboth, Mild | 0 | 0.001 |
| Blood Pressure Increased-non-SAE, NR, Mod | 0 | 0.001 |
| Blood Pressure Increased-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Blood Pressure Increased-non-SAE, RIGIV, Mod | 0 | 0.001 |
| Blood Pressure Increased-non-SAE, RrHu, Mild | 0 | 0.001 |
| BP Systolic Increased-non-SAE, RIGIV, Mild | 0.003 | 0 |
| Blood Urea Increased-non-SAE, NR, Mild | 0 | 0.001 |
| Body Fat Disorder-non-SAE, NR, Mild | 0 | 0.001 |
| Body Tinea-non-SAE, NR, Mild | 0.003 | 0 |
| Body Tinea-non-SAE, NR, Mod | 0 | 0.001 |
| Bone Pain-non-SAE, NR, Mild | 0 | 0.001 |
| Breast Pain-non-SAE, NR, Mild | 0.003 | 0 |
| Bronchal Hyperreactivity-non-SAE, NR, Mild | 0 | 0.001 |
| Bronchitis-non-SAE, NR, Mild | 0.011 | 0.002 |
| Bronchitis-non-SAE, NR, Mod | 0.005 | 0.007 |
| Bronchitis-SAE, NR, Mod | 0.003 | 0 |
| Bronchospasm-non-SAE, NR, Mod | 0 | 0.001 |
| Burn Infection-non-SAE, NR, Mild | 0 | 0.001 |
| Burning Sensation-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Burning Sensation-non-SAE, RIGIV, Mod | 0 | 0.001 |
| Burning Sensation-non-SAE, RrHu, Mild | 0 | 0.001 |
| Bursitis-non-SAE, NR, Mild | 0.003 | 0 |
| Bursitis-non-SAE, NR, Mod | 0 | 0.001 |
| Candidiasis-non-SAE, NR, Mild | 0.003 | 0 |
| Candidiasis-non-SAE, NR, Mod | 0.003 | 0.001 |
| Cardiac Murmur-non-SAE, NR, Mild | 0 | 0.001 |
| Cellulitis-non-SAE, NR, Mild | 0 | 0.001 |
| Cellulitis-non-SAE, NR, Mod | 0 | 0.003 |
| Cellulitis-non-SAE, Rboth, Mod | 0 | 0.001 |
| Cerumen Impaction-non-SAE, NR, Mild | 0 | 0.002 |
| Cervical Dysplasia-SAE, NR, Mild | 0.003 | 0.001 |
| Cheilitis-non-SAE, NR, Mild | 0.005 | 0 |
| Chest Pain-non-SAE, NR, Mild | 0 | 0.002 |
| Chills-non-SAE, NR, Mild | 0 | 0.003 |
| Chills-non-SAE, RIGIV, Mild | 0.016 | 0.001 |
| Chills-non-SAE, RIGIV, Mod | 0.008 | 0 |
| Chills-non-SAE, Rboth, Mild | 0 | 0.001 |
| COPD-non-SAE, NR, Mod | 0 | 0.002 |
| COPD-non-SAE, NR, Severe | 0.003 | 0 |
| Chronic Sinusitis-non-SAE, NR, Mild | 0 | 0.004 |
| Chronic Sinusitis-non-SAE, NR, Mod | 0.003 | 0.001 |
| Concussion-non-SAE, NR, Mod | 0.003 | 0 |
| Confusional State-non-SAE, NR, Mod | 0 | 0.001 |
| Confusional State-non-SAE, RIGIV, Mild | 0.003 | 0 |
| Conjunctivitis-non-SAE, NR, Mild | 0.003 | 0.002 |
| Conjunctivitis Allergic-non-SAE, NR, Mild | 0.003 | 0 |
| Conjunctivitis Allergic-non-SAE, NR, Mod | 0.003 | 0 |
| Conjunctivitis Bacterial-non-SAE, NR, Mild | 0.003 | 0.001 |
| Conjunctivitis Bacterial-non-SAE, NR, Mod | 0 | 0.001 |
| Conjunctivitis Bacterial-non-SAE, NR, Severe | 0 | 0.001 |
| Constipation-non-SAE, NR, Mild | 0 | 0.003 |
| Contusion-non-SAE, NR, Mild | 0.003 | 0.004 |
| Contusion-non-SAE, NR, Mod | 0.003 | 0 |
| Contusion-non-SAE, RIGIV, Mod | 0 | 0.001 |
| Coombs Test Positive-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Costochondritis-non-SAE, NR, Mod | 0 | 0.001 |
| Cough-non-SAE, NR, Mild | 0.008 | 0.005 |
| Cough-non-SAE, NR, Mod | 0 | 0.002 |
| Cough-non-SAE, RIGIV, Mild | 0.003 | 0 |
| Cushingoid-non-SAE, NR, Mild | 0 | 0.001 |
| Cystitis-non-SAE, NR, Mild | 0 | 0.001 |
| Deafness Neurosensory-non-SAE, NR, Mild | 0.003 | 0 |
| Decreased Appetite-non-SAE, NR, Mild | 0.003 | 0.001 |
| Decreased Appetite-non-SAE, RrHu, Mild | 0 | 0.001 |
| Decreased Appetite-non-SAE, Rboth, Mild | 0 | 0.002 |
| Dehydration-non-SAE, NR, Mod | 0 | 0.002 |
| Dental Caries-non-SAE, NR, Mild | 0 | 0.002 |
| Dental Caries-non-SAE, NR, Mod | 0 | 0.003 |
| Depressed Mood-non-SAE, NR, Mild | 0 | 0.001 |
| Depression-non-SAE, NR, Severe | 0 | 0.001 |
| Dermal Cyst-non-SAE, NR, Mild | 0 | 0.001 |
| Dermatitis-non-SAE, NR, Mild | 0 | 0.002 |
| Dermatitis-non-SAE, NR, Mod | 0.003 | 0 |
| Dermatitis Acneiform-non-SAE, NR, Mod | 0.003 | 0 |
| Dermatitis Contact-non-SAE, NR, Mild | 0 | 0.002 |
| Dermatitis Contact-non-SAE, NR, Mod | 0.005 | 0.002 |
| Dermatitis Infected-non-SAE, NR, Mild | 0 | 0.002 |
| Dermatitis Infected-non-SAE, NR, Mod | 0 | 0.001 |
| Dermatitis Infected-non-SAE, NR, Severe | 0 | 0.001 |
| Device Failure-non-SAE, NR, Mild | 0.005 | 0.001 |
| Device Failure-non-SAE, NR, Mod | 0 | 0.002 |
| Diarrhoea-non-SAE, NR, Mild | 0.008 | 0.005 |
| Diarrhoea-non-SAE, NR, Mod | 0.005 | 0.004 |
| Diarrhoea-non-SAE, RIGIV, Mild | 0.003 | 0.001 |
| Diarrhoea-non-SAE, RIGIV, Mod | 0.003 | 0 |
| Diarrhoea Haemorrhagic-non-SAE, NR, Mild | 0.003 | 0 |
| Diarrhoea Infectious-non-SAE, NR, Mild | 0 | 0.001 |
| Diastolic Dysfunction-non-SAE, NR, Mild | 0 | 0.001 |
| Disaccharide Metabolism Disorder-non-SAE, NR, Mild | 0 | 0.001 |
| Disturbance in Attention-non-SAE, NR, Mild | 0 | 0.002 |
| Diverticulitis-non-SAE, NR, Mod | 0.003 | 0 |
| Dizziness-non-SAE, NR, Mild | 0.005 | 0.006 |
| Dizziness-non-SAE, NR, Mod | 0 | 0.002 |
| Dizziness-non-SAE, RIGIV, Mild | 0 | 0.003 |
| Dizziness-non-SAE, RIGIV, Mod | 0.003 | 0 |
| Drug Eruption-non-SAE, NR, Mod | 0.003 | 0 |
| Dry Eye-non-SAE, NR, Mod | 0 | 0.001 |
| Dry Mouth-non-SAE, NR, Mild | 0 | 0.001 |
| Dry Skin-non-SAE, NR, Mild | 0 | 0.003 |
| Dysmenorrhoea-non-SAE, NR, Mild | 0 | 0.001 |
| Dyspepsia-non-SAE, NR, Mild | 0 | 0.002 |
| Dyspepsia-non-SAE, NR, Mod | 0 | 0.001 |
| Dyspepsia-non-SAE, RIGIV, Mild | 0.003 | 0 |
| Dysphagia-non-SAE, NR, Mild | 0 | 0.001 |
| Dysphagia-non-SAE, NR, Mod | 0 | 0.001 |
| Dyspnoea-non-SAE, NR, Mild | 0.003 | 0 |
| Dyspnoea-non-SAE, NR, Mod | 0.003 | 0 |
| Dyspnoea-non-SAE, RIGIV, Mild | 0.003 | 0 |
| Dysuria-non-SAE, NR, Mild | 0 | 0.002 |
| Ear Infection-non-SAE, NR, Mild | 0.005 | 0.002 |
| Ear Infection-non-SAE, NR, Mod | 0.003 | 0.001 |
| Ear Pain-non-SAE, NR, Mild | 0.008 | 0.002 |
| Ear Pain-non-SAE, NR, Mod | 0 | 0.001 |
| Ecchymosis-non-SAE, NR, Mild | 0 | 0.001 |
| Eczema-non-SAE, NR, Mild | 0 | 0.001 |
| Eczema-non-SAE, NR, Mod | 0 | 0.001 |
| Eczema-non-SAE, NR, Severe | 0.003 | 0 |
| Eosinophil Count-non-SAE, NR, Mild | 0 | 0.001 |
| Epitaxis-non-SAE, NR, Mild | 0.005 | 0.003 |
| Epitaxis-non-SAE, NR, Mod | 0.005 | 0.002 |
| Erythema-non-SAE, NR, Mild | 0.003 | 0 |
| Erythema-non-SAE, RIGIV, Mod | 0 | 0.001 |
| Erythema-non-SAE, RrHu, Mild | 0 | 0.001 |
| Erythema-non-SAE, Rboth, Mild | 0 | 0.001 |
| Erythema-non-SAE, Rboth, Mod | 0 | 0.001 |
| Eustachian Tube Dysfunction-non-SAE, NR, Mild | 0.003 | 0 |
| Excoriation-non-SAE, NR, Mild | 0.005 | 0.002 |
| Extravasation Blood-non-SAE, Rboth, Mild | 0 | 0.001 |
| Eye Irritation-non-SAE, NR, Mild | 0 | 0.001 |
| Eye Pruritus-non-SAE, NR, Mod | 0 | 0.001 |
| Eye Swelling-non-SAE, NR, Mod | 0 | 0.001 |
| Fall-non-SAE, NR, Mild | 0 | 0.001 |
| Fall-non-SAE, NR, Mod | 0 | 0.001 |
| Fatigue-non-SAE, NR, Mild | 0.003 | 0.004 |
| Fatigue-non-SAE, NR, Mod | 0.003 | 0.002 |
| Fatigue-non-SAE, RIGIV, Mild | 0.022 | 0.007 |
| Fatigue-non-SAE, RIGIV, Mod | 0 | 0.003 |
| Fatigue-non-SAE, Rboth, Mild | 0 | 0.003 |
| Feeling Abnormal-non-SAE, Rboth, Mod | 0 | 0.001 |
| Feeling Cold-non-SAE, RIGIV, Mild | 0.005 | 0 |
| Flatulence-non-SAE, NR, Mild | 0 | 0.001 |
| Flatulence-non-SAE, NR, Mod | 0 | 0.001 |
| Food Poisoning-non-SAE, NR, Mod | 0 | 0.001 |
| Free Haemoglobin Present-non-SAE, NR, Mild | 0.003 | 0.001 |
| Free Haemoglobin Present-non-SAE, NR, Severe | 0.003 | 0 |
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe
| Number of AEs per infusion | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Gait Disturbance-non-SAE, NR, Mild | 0 | 0.001 |
| Gastroenteritis-non-SAE, NR, Mild | 0 | 0.003 |
| Gastroenteritis-non-SAE, NR, Mod | 0.005 | 0.002 |
| Gastroenteritis-non-SAE, RIGIV, Mild | 0.003 | 0 |
| Gastroenteritis-SAE, NR, Mod | 0 | 0.001 |
| Gastroenteritis Bacterial-non-SAE, NR, Mod | 0 | 0.001 |
| Gastroenteritis Viral-non-SAE, NR, Mild | 0.008 | 0.005 |
| Gastroenteritis Viral-non-SAE, NR, Mod | 0 | 0.004 |
| Gastroenteritis Viral-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Gastrointestinal Haemorrhage-non-SAE, NR, Severe | 0 | 0.001 |
| Gastrooesophageal Reflux Disease-non-SAE, NR, Mild | 0.003 | 0.002 |
| Gastrooesophageal Reflux Disease-non-SAE, NR, Mod | 0.003 | 0 |
| Genital Herpes-non-SAE, NR, Mild | 0.003 | 0 |
| Genital Swelling-non-SAE, Rboth, Mod | 0 | 0.001 |
| Goitre-non-SAE, NR, Mild | 0.003 | 0 |
| Gout-non-SAE, NR, Mild | 0 | 0.001 |
| Grand Mal Convulsion-non-SAE, NR, Severe | 0.003 | 0 |
| Grand Mal Convulsion-SAE, NR, Severe | 0 | 0.001 |
| Gravitational Oedema-non-SAE, Rboth, Mod | 0 | 0.001 |
| Groin Pain-non-SAE, NR, Mild | 0 | 0.001 |
| Groin Pain-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Groin Pain-non-SAE, RrHu, Mod | 0 | 0.001 |
| Haematoma-non-SAE, NR, Mild | 0.003 | 0.001 |
| Haematoma-non-SAE, NR, Mod | 0 | 0.001 |
| Haematuria-non-SAE, NR, Mild | 0 | 0.001 |
| Haemoglobin Abnormal-non-SAE, NR, Mild | 0 | 0.001 |
| Haemorrhoids-non-SAE, NR, Mild | 0 | 0.002 |
| Hand Fracture-non-SAE, NR, Mod | 0 | 0.001 |
| Headache-non-SAE, NR, Mild | 0.036 | 0.014 |
| Headache-non-SAE, NR, Mod | 0.003 | 0.003 |
| Headache-non-SAE, NR, Severe | 0.003 | 0 |
| Headache-non-SAE, RIGIV, Mild | 0.068 | 0.012 |
| Headache-non-SAE, RIGIV, Mod | 0.033 | 0.004 |
| Headache-non-SAE, RIGIV, Severe | 0.003 | 0 |
| Headache-non-SAE, Rboth, Mild | 0 | 0.008 |
| Headache-non-SAE, Rboth, Mod | 0 | 0.007 |
| Headache-SAE, NR, Severe | 0 | 0.001 |
| Hearing Impaired-non-SAE, NR, Mild | 0 | 0.001 |
| Heart Rate Increased-non-SAE, RIGIV, Mild | 0.011 | 0 |
| Heat Rash-non-SAE, NR, Mild | 0 | 0.001 |
| Heat Stroke-non-SAE, NR, Mod | 0 | 0.001 |
| Herpes Simplex Ophthalmic-non-SAE, NR, Mod | 0 | 0.001 |
| Herpes Zoster-non-SAE, NR, Mod | 0 | 0.001 |
| Hiatus Hernia-non-SAE, NR, Mod | 0 | 0.001 |
| Hot Flush-non-SAE, RIGIV, Mild | 0.003 | 0 |
| Hyperaesthesia-non-SAE, NR, Mild | 0 | 0.001 |
| Hypercholesterolaemia-non-SAE, NR, Mod | 0 | 0.001 |
| Hyperkeratosis-non-SAE, NR, Mild | 0 | 0.001 |
| Hypertension-non-SAE, NR, Mod | 0 | 0.004 |
| Hypertension-non-SAE, RIGIV, Mild | 0 | 0.002 |
| Hypertension-non-SAE, RIGIV, Mod | 0 | 0.001 |
| Hypertonia-non-SAE, NR, Mild | 0 | 0.001 |
| Hypothyroidism-non-SAE, NR, Mild | 0 | 0.001 |
| Idiopathic Urticaria-non-SAE, NR, Mod | 0.003 | 0 |
| Increased Upper Airway Secretion-non-SAE, NR, Mild | 0.005 | 0 |
| Infected Bites-non-SAE, NR, Mild | 0 | 0.002 |
| Infected Bites-non-SAE, NR, Mod | 0.003 | 0.001 |
| Infection-non-SAE, NR, Mod | 0 | 0.002 |
| Influenza-non-SAE, NR, Mild | 0.003 | 0.002 |
| Influenza-non-SAE, NR, Mod | 0.011 | 0.003 |
| Influenza Like Illness-non-SAE, NR, Mild | 0 | 0.001 |
| Infusion Related Reaction-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Infusion Related Reaction-non-SAE, RIGIV, Mod | 0.003 | 0 |
| Infusion Related Reaction-non-SAE, Rboth, Mild | 0 | 0.001 |
| Infusion Related Reaction-non-SAE, Rboth, Mod | 0 | 0.001 |
| Infusion Site Discomfort-non-SAE, RIGIV, Mild | 0 | 0.005 |
| Infusion Site Discomfort-non-SAE, RrHu, Mod | 0 | 0.001 |
| Infusion Site Discomfort-non-SAE, Rboth, Mild | 0 | 0.013 |
| Infusion Site Discomfort-non-SAE, Rboth, Mod | 0 | 0.007 |
| Infusion Site Erythema-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Infusion Site Erythema-non-SAE, RrHu, Mild | 0 | 0.002 |
| Infusion Site Erythema-non-SAE, Rboth, Mild | 0 | 0.018 |
| Infusion Site Erythema-non-SAE, Rboth, Mod | 0 | 0.004 |
| Infusion Site Extravasation-non-SAE, NR, Mild | 0.005 | 0 |
| Infusion Site Haematoma-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Infusion Site Haemorrhage-non-SAE, Rboth, Mild | 0 | 0.001 |
| Infusion Site Hypersensitivity-non-SAE, NR, Severe | 0 | 0.001 |
| Infusion Site Hypersensitivity-non-SAE, Rboth, Mod | 0 | 0.001 |
| Infusion Site Mass-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Infusion Site Mass-non-SAE, Rboth, Mild | 0 | 0.002 |
| Infusion Site Oedema-non-SAE, Rboth, Mild | 0 | 0.004 |
| Infusion Site Oedema-non-SAE, Rboth, Mod | 0 | 0.004 |
| Infusion Site Pain-non-SAE, NR, Mild | 0 | 0.002 |
| Infusion Site Pain-non-SAE, RIGIV, Mild | 0.003 | 0.011 |
| Infusion Site Pain-non-SAE, RIGIV, Mod | 0 | 0.005 |
| Infusion Site Pain-non-SAE, RrHu, Mild | 0 | 0.031 |
| Infusion Site Pain-non-SAE, RrHu, Mod | 0 | 0.001 |
| Infusion Site Pain-non-SAE, Rboth, Mild | 0 | 0.017 |
| Infusion Site Pain-non-SAE, Rboth, Mod | 0 | 0.014 |
| Infusion Site Pain-non-SAE, Rboth, Severe | 0 | 0.001 |
| Infusion Site Pruritus-non-SAE, RIGIV, Mild | 0 | 0.002 |
| Infusion Site Pruritus-non-SAE, RrHu, Mild | 0 | 0.004 |
| Infusion Site Pruritus-non-SAE, Rboth, Mild | 0 | 0.005 |
| Infusion Site Pruritus-non-SAE, Rboth, Mod | 0 | 0.004 |
| Infusion Site Reaction-non-SAE, Rboth, Mild | 0 | 0.001 |
| Infusion Site Reaction-non-SAE, Rboth, Mod | 0 | 0.002 |
| Infusion Site Swelling-non-SAE, RIGIV, Mild | 0 | 0.002 |
| Infusion Site Swelling-non-SAE, Rboth, Mild | 0 | 0.003 |
| Infusion Site Swelling-non-SAE, Rboth, Mod | 0 | 0.004 |
| Infusion Site Swelling-non-SAE, Rboth, Severe | 0 | 0.001 |
| Infusion Site Warmth-non-SAE, Rboth, Mild | 0 | 0.002 |
| Ingrowing Nail-non-SAE, NR, Mod | 0 | 0.001 |
| Injection Site Erythema-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Injury-non-SAE, NR, Mild | 0.003 | 0 |
| Insomnia-non-SAE, NR, Mild | 0.003 | 0 |
| Intervertebral Disc Protrusion-non-SAE, NR, Mod | 0.003 | 0 |
| Irritable Bowel Syndrome-non-SAE, NR, Mild | 0 | 0.001 |
| Irritable Bowel Syndrome-non-SAE, NR, Mod | 0 | 0.002 |
| Joint Effusion-non-SAE, NR, Mild | 0 | 0.001 |
| Joint Effusion-non-SAE, NR, Mod | 0 | 0.001 |
| Joint Injury-non-SAE, NR, Mod | 0.003 | 0.001 |
| Joint Range of Motion Decreased-non-SAE, NR, Mod | 0 | 0.002 |
| Joint Sprain-non-SAE, NR, Mild | 0 | 0.001 |
| Joint Sprain-non-SAE, NR, Mod | 0 | 0.002 |
| Joint Swelling-non-SAE, NR, Mild | 0 | 0.001 |
| Jugular Vein Distension-non-SAE, NR, Mild | 0 | 0.001 |
| Lethargy-non-SAE, NR, Mild | 0 | 0.001 |
| Lethargy-non-SAE, RIGIV, Mod | 0.003 | 0 |
| Ligament Injury-non-SAE, NR, Mod | 0 | 0.001 |
| Ligament Sprain-non-SAE, NR, Mod | 0 | 0.001 |
| Limb Injury-non-SAE, NR, Mild | 0.003 | 0 |
| Lip Injury-non-SAE, NR, Mild | 0 | 0.001 |
| Lip Ulceration-non-SAE, NR, Mild | 0 | 0.001 |
| Local Swelling-non-SAE, RIGIV, Mild | 0 | 0.003 |
| Local Swelling-non-SAE, Rboth, Mild | 0 | 0.003 |
| Localised Infection-non-SAE, NR, Mild | 0 | 0.001 |
| Localised Oedema-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Localised Oedema-non-SAE, Rboth, Mod | 0 | 0.001 |
| Lung Infection-non-SAE, NR, Mod | 0.003 | 0 |
| Lung Infection-non-SAE, NR, Severe | 0.003 | 0 |
| Lymph Gland Infection-non-SAE, NR, Mod | 0.003 | 0 |
| Lymph Node Pain-non-SAE, NR, Mild | 0.003 | 0 |
| Lymph Node Pain-non-SAE, NR, Mod | 0 | 0.001 |
| Lymph Node Palpable-non-SAE, NR, Mild | 0.003 | 0 |
| Lymphadenitis-non-SAE, NR, Mod | 0.003 | 0 |
| Lymphadenopathy-non-SAE, NR, Mild | 0.005 | 0.007 |
| Lymphangitis-non-SAE, NR, Mod | 0 | 0.001 |
| Lymphocyte Count Decreased-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Lymphoedema-non-SAE, NR, Severe | 0.003 | 0 |
| Malaise-non-SAE, NR, Mild | 0 | 0.002 |
| Malaise-non-SAE, NR, Mod | 0 | 0.001 |
| Malaise-non-SAE, RIGIV, Mod | 0.003 | 0 |
| Malaise-non-SAE, RrHu, Mild | 0 | 0.001 |
| Malaise-non-SAE, RrHu, Mod | 0 | 0.001 |
| Memory Impairment-non-SAE, NR, Mod | 0 | 0.001 |
| Migraine-non-SAE, NR, Mild | 0.003 | 0.001 |
| Migraine-non-SAE, NR, Mod | 0 | 0.002 |
| Migraine-non-SAE, NR, Severe | 0.003 | 0 |
| Migraine-non-SAE, RIGIV, Mild | 0.003 | 0.001 |
| Migraine-non-SAE, RIGIV, Mod | 0.003 | 0.004 |
| Migraine-non-SAE, RIGIV, Severe | 0 | 0.001 |
| Migraine-non-SAE, Rboth, Mod | 0 | 0.001 |
| Molluscum Contagiosum-non-SAE, NR, Mild | 0.005 | 0 |
| Mouth Ulceration-non-SAE, NR, Mild | 0.003 | 0 |
| Multiple Sclerosis Relapse-non-SAE, NR, Mod | 0 | 0.001 |
| Muscle Fatigue-non-SAE, NR, Mild | 0 | 0.001 |
| Muscle Injury-non-SAE, NR, Mild | 0 | 0.002 |
| Muscle Spasms-non-SAE, NR, Mild | 0 | 0.001 |
| Muscle Spasms-non-SAE, RIGIV, Mild | 0.003 | 0 |
| Muscle Strain-non-SAE, NR, Mild | 0.003 | 0.001 |
| Muscle Strain-non-SAE, NR, Mod | 0 | 0.001 |
| Muscular Weakness-non-SAE, NR, Mild | 0.003 | 0 |
| Musculoskeletal Chest Pain-non-SAE, NR, Mild | 0 | 0.001 |
| Musculoskeletal Chest Pain-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Musculoskeletal Pain-non-SAE, NR, Mild | 0.005 | 0 |
| Musculoskeletal Pain-non-SAE, NR, Mod | 0.003 | 0.001 |
| Musculoskeletal Stiffness-non-SAE, NR, Mild | 0.003 | 0.001 |
| Myalgia-non-SAE, NR, Mild | 0.008 | 0.004 |
| Myalgia-non-SAE, NR, Mod | 0.003 | 0.004 |
| Myalgia-non-SAE, NR, Severe | 0 | 0.001 |
| Myalgia-non-SAE, RIGIV, Mild | 0 | 0.005 |
| Myalgia-non-SAE, RIGIV, Mod | 0.003 | 0.001 |
| Myalgia-non-SAE, Rboth, Mild | 0 | 0.003 |
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); ; RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Resp.-Respiratory WBC - White blood cells
| Number of AEs per infusion | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Nasal Congestion-non-SAE, NR, Mild | 0.011 | 0.003 |
| Nasal Congestion-non-SAE, NR, Mod | 0 | 0.002 |
| Nasal Congestion-non-SAE, RIGIV, Mild | 0 | 0.003 |
| Nasal Discomfort-non-SAE, NR, Mild | 0 | 0.001 |
| Nasal Mucosal Discolouration-non-SAE, NR, Mild | 0 | 0.001 |
| Nasal Turbinate Hypertrophy-non-SAE, NR, Mild | 0 | 0.001 |
| Nasopharyngitis-non-SAE, NR, Mild | 0.011 | 0.007 |
| Nausea-non-SAE, NR, Mild | 0.008 | 0.015 |
| Nausea-non-SAE, NR, Mod | 0.005 | 0.003 |
| Nausea-non-SAE, RIGIV, Mild | 0.019 | 0.001 |
| Nausea-non-SAE, RIGIV, Mod | 0.003 | 0 |
| Nausea-non-SAE, Rboth, Mild | 0 | 0.004 |
| Neck Pain-non-SAE, NR, Mild | 0.003 | 0.001 |
| Night Sweats-non-SAE, NR, Mild | 0.003 | 0 |
| Night Sweats-non-SAE, NR, Mod | 0 | 0.001 |
| Nodule-non-SAE, Rboth, Mild | 0 | 0.002 |
| Oedema-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Oedema Genital-non-SAE, Rboth, Severe | 0 | 0.001 |
| Oedema Peripheral-non-SAE, NR, Mild | 0 | 0.001 |
| Oedema Peripheral-non-SAE, NR, Mod | 0 | 0.001 |
| Oedema Peripheral-non-SAE, Rboth, Mod | 0 | 0.002 |
| Oesophagitis-non-SAE, NR, Mild | 0 | 0.001 |
| Onychomycosis-non-SAE, NR, Mild | 0 | 0.001 |
| Oral Candidiasis-non-SAE, NR, Mod | 0 | 0.001 |
| Oral Fungal Infection-non-SAE, NR, Mild | 0 | 0.001 |
| Oral Herpes-non-SAE, NR, Mild | 0.003 | 0.002 |
| Oral Herpes-non-SAE, NR, Mod | 0 | 0.001 |
| Oral Pain-non-SAE, NR, Mild | 0 | 0.001 |
| Oral Pain-non-SAE, RrHu, Severe | 0 | 0.001 |
| Oropharyngeal Pain-non-SAE, NR, Mild | 0.003 | 0.004 |
| Oropharyngeal Pain-non-SAE, NR, Mod | 0.005 | 0.001 |
| Osteoarthritis-non-SAE, NR, Mod | 0 | 0.001 |
| Osteopenia-non-SAE, NR, Mild | 0 | 0.001 |
| Osteopenia-non-SAE, NR, Mod | 0 | 0.001 |
| Osteoporosis-non-SAE, NR, Mild | 0 | 0.001 |
| Otitis Externa-non-SAE, NR, Mild | 0 | 0.001 |
| Otitis Externa-non-SAE, NR, Mod | 0 | 0.001 |
| Otitis Media-non-SAE, NR, Mod | 0.003 | 0.001 |
| Pain-non-SAE, NR, Mild | 0.003 | 0.004 |
| Pain-non-SAE, NR, Mod | 0.003 | 0.001 |
| Pain-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Pain-non-SAE, RIGIV, Mod | 0.005 | 0.001 |
| Pain-non-SAE, Rboth, Mild | 0 | 0.001 |
| Pain-non-SAE, Rboth, Mod | 0 | 0.001 |
| Pain in Extremity-non-SAE, NR, Mild | 0.005 | 0.001 |
| Pain in Extremity-non-SAE, NR, Mod | 0.003 | 0.002 |
| Pain in Extremity-non-SAE, RIGIV, Mod | 0.005 | 0 |
| Pain in Extremity-non-SAE, RIGIV, Severe | 0.003 | 0 |
| Pain in Extremity-non-SAE, Rboth, Mild | 0 | 0.003 |
| Pain in Extremity-non-SAE, Rboth, Mod | 0 | 0.002 |
| Palpitations-non-SAE, NR, Mild | 0.003 | 0.001 |
| Papule-non-SAE, NR, Mild | 0 | 0.001 |
| Peptic Ulcer Haemorrhage-SAE, NR, Severe | 0.003 | 0 |
| Periorbital Haematoma-non-SAE, NR, Mild | 0 | 0.001 |
| Peripheral Nerve Injury-non-SAE, NR, Mild | 0 | 0.001 |
| Pertussis-non-SAE, NR, Mod | 0 | 0.001 |
| Petit Mal Epilepsy-SAE, NR, Severe | 0 | 0.001 |
| Pharyngeal Erythema-non-SAE, NR, Mild | 0.003 | 0.003 |
| Pharyngitis-non-SAE, NR, Mild | 0.003 | 0.004 |
| Pharyngitis-non-SAE, NR, Mod | 0.003 | 0 |
| Pharyngitis Streptococcal-non-SAE, NR, Mod | 0 | 0.004 |
| Pneumonia-non-SAE, NR, Mild | 0 | 0.001 |
| Pneumonia-non-SAE, NR, Mod | 0 | 0.001 |
| Pneumonia Bacterial-non-SAE, NR, Mod | 0 | 0.001 |
| Post Procedural Infection-non-SAE, NR, Mild | 0.003 | 0.002 |
| Post Procedural Infection-non-SAE, NR, Mod | 0 | 0.004 |
| Postictal Paralysis-non-SAE, NR, Mod | 0 | 0.001 |
| Postoperative Wound Infection-non-SAE, NR, Mod | 0 | 0.001 |
| Procedural Pain-non-SAE, NR, Mild | 0 | 0.002 |
| Procedural Pain-non-SAE, NR, Mod | 0 | 0.001 |
| Productive Cough-non-SAE, NR, Mild | 0.003 | 0.001 |
| Pruritus-non-SAE, NR, Mild | 0.003 | 0 |
| Pruritus-non-SAE, RIGIV, Mild | 0.003 | 0 |
| Pruritus-non-SAE, Rboth, Mild | 0 | 0.001 |
| Pruritus-non-SAE, Rboth, Mod | 0 | 0.001 |
| Pruritus Generalized-non-SAE, NR, Mild | 0.003 | 0 |
| Pseudomonas Infection-non-SAE, NR, Mod | 0 | 0.001 |
| Psoriasis-non-SAE, NR, Mod | 0 | 0.001 |
| Pyrexia-non-SAE, NR, Mild | 0.008 | 0.010 |
| Pyrexia-non-SAE, NR, Mod | 0.005 | 0.001 |
| Pyrexia-non-SAE, RIGIV, Mild | 0.011 | 0.005 |
| Pyrexia-non-SAE, RIGIV, Mod | 0.005 | 0.002 |
| Pyrexia-non-SAE, Rboth, Mild | 0 | 0.002 |
| Rales-non-SAE, NR, Mild | 0 | 0.001 |
| Rales-non-SAE, NR, Mod | 0 | 0.001 |
| Rash-non-SAE, NR, Mild | 0.005 | 0.004 |
| Rash-non-SAE, NR, Mod | 0 | 0.001 |
| Rash Erythematous-non-SAE, NR, Mild | 0 | 0.001 |
| Rash Maculo-Papular-non-SAE, Rboth, Mild | 0 | 0.001 |
| Rash Pustular-non-SAE, NR, Mild | 0 | 0.001 |
| Rash Pustular-non-SAE, NR, Mod | 0.003 | 0 |
| Rash Papular-non-SAE, NR, Mild | 0 | 0.001 |
| Respiratory Failure-SAE, NR, Severe | 0 | 0.001 |
| Respiratory Rate Increased-non-SAE, NR, Mild | 0 | 0.001 |
| Respiratory Tract Congestion-non-SAE, NR, Mild | 0 | 0.001 |
| Respiratory Tract Infection-non-SAE, NR, Mild | 0.003 | 0.001 |
| Respiratory Tract Infection-non-SAE, NR, Mod | 0.003 | 0.003 |
| Respiratory Tract Infection Viral-non-SAE, NR, Mod | 0.003 | 0 |
| Rhinitis Allergic-non-SAE, NR, Mild | 0.003 | 0.003 |
| Rhinitis Allergic-non-SAE, NR, Mod | 0.008 | 0.001 |
| Rhinitis Allergic-non-SAE, RIGIV, Mod | 0.003 | 0 |
| Rhinorrhoea-non-SAE, NR, Mild | 0.003 | 0.001 |
| Road Traffic Accident-non-SAE, NR, Mod | 0 | 0.002 |
| Scleritis-non-SAE, NR, Mild | 0.003 | 0.001 |
| Scleritis-non-SAE, NR, Mod | 0 | 0.001 |
| Scratch-non-SAE, NR, Mild | 0.003 | 0 |
| Seborrhoeic Dermatitis-non-SAE, NR, Mild | 0 | 0.001 |
| Sicca Syndrome-non-SAE, NR, Mod | 0 | 0.001 |
| Sinus Congestion-non-SAE, NR, Mild | 0.003 | 0 |
| Sinus Headache-non-SAE, NR, Mild | 0.003 | 0 |
| Sinusitis-non-SAE, NR, Mild | 0.016 | 0.022 |
| Sinusitis-non-SAE, NR, Mod | 0.036 | 0.023 |
| Sinusitis-non-SAE, NR, Severe | 0 | 0.001 |
| Sinusitis-non-SAE, RIGIV, Mod | 0 | 0.001 |
| Skeletal Injury-non-SAE, NR, Mild | 0 | 0.001 |
| Skeletal Injury-non-SAE, NR, Mod | 0 | 0.001 |
| Skin Hyperpigmentation-non-SAE, Rboth, Mild | 0 | 0.001 |
| Skin Laceration-non-SAE, NR, Mild | 0 | 0.001 |
| Skin Laceration-non-SAE, NR, Mod | 0 | 0.001 |
| Skin Lesion-non-SAE, NR, Mild | 0.005 | 0.001 |
| Skin Lesion-non-SAE, NR, Mod | 0.003 | 0 |
| Skin Lesion-non-SAE, RIGIV, Mild | 0 | 0.002 |
| Skin Papilloma-non-SAE, NR, Mod | 0.003 | 0 |
| Spinal Osteoarthritis-non-SAE, NR, Mild | 0 | 0.002 |
| Squamous Cell Carcinoma-non-SAE, NR, Mod | 0.003 | 0.001 |
| Status Epilepticus-SAE, NR, Severe | 0 | 0.001 |
| Suicidal Ideation-non-SAE, NR, Mild | 0.003 | 0 |
| Sunburn-non-SAE, NR, Mild | 0 | 0.001 |
| Swelling-non-SAE, Rboth, Mild | 0 | 0.001 |
| Swelling-non-SAE, Rboth, Mod | 0 | 0.003 |
| Syncope-non-SAE, NR, Mild | 0 | 0.001 |
| Tachycardia-non-SAE, NR, Mild | 0 | 0.003 |
| Tachycardia-non-SAE, NR, Mod | 0 | 0.001 |
| Therapy Cessation-non-SAE, NR, Severe | 0 | 0.001 |
| Thrombosis-non-SAE, NR, Severe | 0 | 0.001 |
| Thrombosis-SAE, NR, Mod | 0 | 0.001 |
| Tinea Infection-non-SAE, NR, Mild | 0.005 | 0 |
| Tongue Coated-non-SAE, NR, Mild | 0 | 0.001 |
| Tonsillar Hypertrophy-non-SAE, NR, Mod | 0 | 0.001 |
| Tonsillar Hypertrophy-SAE, NR, Mild | 0 | 0.001 |
| Tooth Abscess-non-SAE, NR, Mild | 0.003 | 0 |
| Tooth Abscess-non-SAE, NR, Mod | 0 | 0.001 |
| Tooth Impacted-non-SAE, NR, Mod | 0 | 0.001 |
| Tooth Infection-non-SAE, NR, Mod | 0 | 0.001 |
| Toothache-non-SAE, NR, Mod | 0 | 0.001 |
| Tongue Injury-non-SAE, NR, Mild | 0 | 0.001 |
| Tremor-non-SAE, NR, Mild | 0 | 0.001 |
| Tricuspid Valve Incompetence-non-SAE, NR, Mild | 0 | 0.001 |
| Tympanic Membrane Disorder-non-SAE, NR, Mild | 0.003 | 0 |
| Tympanic Membrane Hyperaemia-non-SAE, NR, Mild | 0 | 0.002 |
| Upper Airway Cough Syndrome-non-SAE, NR, Mild | 0 | 0.001 |
| Upper Resp. Tract Infection-non-SAE, NR, Mild | 0.019 | 0.030 |
| Upper Resp. Tract Infection-non-SAE, NR, Mod | 0.005 | 0.009 |
| Urinary Tract Infection-non-SAE, NR, Mild | 0.003 | 0.002 |
| Urinary Tract Infection-non-SAE, NR, Mod | 0.014 | 0.004 |
| Urine Analysis Abnormal-non-SAE, NR, Mild | 0 | 0.001 |
| Urticaria-non-SAE, NR, Mild | 0 | 0.004 |
| Urticaria-non-SAE, NR, Mod | 0 | 0.001 |
| Urticaria-non-SAE, RIGIV, Mild | 0.003 | 0 |
| Uterine Polyp-non-SAE, NR, Mod | 0 | 0.001 |
| Vaginal Haemorrhage-non-SAE, NR, Mod | 0 | 0.001 |
| Vascular Access Complication-non-SAE, NR, Mild | 0.003 | 0 |
| Vertigo-non-SAE, NR, Mod | 0 | 0.001 |
| Viral Diarrhoea-non-SAE, NR, Mild | 0 | 0.001 |
| Viral Infection-non-SAE, NR, Mild | 0008 | 0.006 |
| Viral Infection-non-SAE, NR, Mod | 0.008 | 0.003 |
| Viral Infection-SAE, NR, Mild | 0.003 | 0 |
| Viral Upper Resp. Tract Infection-non-SAE, NR Mild | 0.003 | 0.007 |
| Viral Upper Resp. Tract Infection-non-SAE, NR, Mod | 0.003 | 0.001 |
| Vision Blurred-non-SAE, NR, Mild | 0 | 0.001 |
| Vitamin D Deficiency-non-SAE, NR, Mild | 0.003 | 0 |
| Vitamin D Deficiency-non-SAE, NR, Mod | 0 | 0.002 |
| Vomiting-non-SAE, NR, Mild | 0.014 | 0.006 |
| Vomiting-non-SAE, NR, Mod | 0 | 0.003 |
| Vomiting-non-SAE, RIGIV, Mild | 0.011 | 0.003 |
| Vomiting-non-SAE, RIGIV, Mod | 0.003 | 0.004 |
| Vomiting-non-SAE, RIGIV, Severe | 0.003 | 0 |
| Vomiting-non-SAE, Rboth, Mod | 0 | 0.001 |
| Vulvovaginal Pruritus-non-SAE, RIGIV, Mild | 0 | 0.001 |
| Weight Decreased-non-SAE, RrHu, Mild | 0 | 0.001 |
| Weight Decreased-non-SAE, RrHu, Mod | 0 | 0.001 |
| Wheezing-non-SAE, NR, Mod | 0 | 0.001 |
| WBC Count Decreased-non-SAE, RIGIV, Mild | 0 | 0.001 |
| White Blood Cells Urine Positive-non-SAE, NR, Mild | 0 | 0.001 |
| WBC Urine Positive-non-SAE, RIGIV Mild | 0.003 | 0 |
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: ADHD-Attention Deficit/Hyperactivity Disorder BP-Blood Pressure COPD- Chronic Obstructive Pulmonary Disease
| Number of AEs per participant | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Abdominal Discomfort-non-SAE, NR, Mod | 0 | 0.012 |
| Abdominal Distension-non-SAE, Rboth, Mild | 0 | 0.012 |
| Abdominal Hernia-non-SAE, NR, Mild | 0 | 0.012 |
| Abdominal Pain-non-SAE, NR, Mild | 0.011 | 0.025 |
| Abdominal Pain-non-SAE, NR, Mod | 0 | 0.012 |
| Abdominal Pain-non-SAE, Rboth, Mild | 0 | 0.037 |
| Abdominal Pain-non-SAE, Rboth, Mod | 0 | 0.012 |
| Abdominal Pain Lower-non-SAE, NR, Mild | 0 | 0.012 |
| Abdominal Pain Upper-non-SAE, NR, Mild | 0.011 | 0.062 |
| Abdominal Pain Upper-non-SAE, NR, Mod | 0.011 | 0 |
| Abdominal Pain Upper-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Abdominal Pain Upper-non-SAE, RIGIV, Mod | 0.011 | 0 |
| Abdominal Pain Upper-non-SAE, Rboth, Mild | 0 | 0.025 |
| Abdominal Tenderness-non-SAE, NR, Mod | 0.011 | 0 |
| Abdominal Tenderness-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Abdominal Tenderness-non-SAE, RIGIV, Mod | 0 | 0.025 |
| Acarodermatitis-non-SAE, NR, Mild | 0 | 0.012 |
| Acne-non-SAE, NR, Mild | 0.011 | 0.012 |
| Acute Sinusitis-non-SAE, NR, Mild | 0.011 | 0 |
| Acute Sinusitis-non-SAE, NR, Mod | 0 | 0.049 |
| Adenoidal Hypertrophy-non-SAE, NR, Mod | 0 | 0.012 |
| Adnexa Uteri Cyst-non-SAE, NR, Mild | 0.011 | 0 |
| Adrenocortical Insufficiency Acute-SAE, NR, Mod | 0 | 0.012 |
| Allergic Respiratory Symptom-non-SAE, NR, Mild | 0 | 0.012 |
| Allergic Sinusitis-non-SAE, NR, Mild | 0.011 | 0 |
| Alopecia-non-SAE, NR, Mild | 0.011 | 0 |
| Animal Bite-non-SAE, NR, Mod | 0.011 | 0 |
| Antibody Test Positive-non-SAE, Rboth, Mod | 0 | 0.012 |
| Anxiety-non-SAE, NR, Mild | 0 | 0.012 |
| Anxiety-non-SAE, NR, Mod | 0.011 | 0 |
| Aphthous Stomatitis-non-SAE, NR, Mild | 0.023 | 0.012 |
| Aphthous Stomatitis-non-SAE, NR, Mod | 0 | 0.012 |
| Arteriosclerosis Coronary Artery-non-SAE, NR, Mild | 0 | 0.012 |
| Arthralgia-non-SAE, NR, Mild | 0 | 0.062 |
| Arthralgia-non-SAE, NR, Mod | 0.011 | 0.074 |
| Arthralgia-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Arthralgia-non-SAE, RIGIV, Mod | 0 | 0.025 |
| Arthritis-non-SAE, NR, Mod | 0.011 | 0.012 |
| Arthropathy-non-SAE, NR, Mod | 0.011 | 0 |
| Arthropod Bite-non-SAE, NR, Mild | 0.023 | 0.025 |
| Arthropod Sting-non-SAE, NR, Mild | 0 | 0.012 |
| Arthropod Sting-non-SAE, NR, Mod | 0.011 | 0 |
| Aspiration-non-SAE, NR, Mild | 0 | 0.012 |
| Asthenia-non-SAE, NR, Mild | 0 | 0.037 |
| Asthenia-non-SAE, NR, Mod | 0.011 | 0 |
| Asthenia-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Asthma-non-SAE, NR, Mild | 0 | 0.049 |
| Asthma-non-SAE, NR, Mod | 0.092 | 0.259 |
| Asthma-non-SAE, NR, Severe | 0 | 0.012 |
| ADHD-non-SAE, NR, Mod | 0 | 0.012 |
| Back Injury-non-SAE, NR, Mod | 0.011 | 0 |
| Back Injury-SAE, NR, Severe | 0 | 0.012 |
| Back Pain-non-SAE, NR, Mild | 0.011 | 0.025 |
| Back Pain-non-SAE, NR, Mod | 0.011 | 0.062 |
| Bacterial Prostatitis-non-SAE, NR, Mild | 0 | 0.012 |
| Blepharitis-non-SAE, NR, Mod | 0.011 | 0 |
| Blister-non-SAE, NR, Mild | 0 | 0.012 |
| Blood Pressure Decreased-non-SAE, NR, Mild | 0 | 0.012 |
| Blood Pressure Decreased-non-SAE, Rboth, Mild | 0 | 0.012 |
| Blood Pressure Increased-non-SAE, NR, Mod | 0 | 0.012 |
| Blood Pressure Increased-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Blood Pressure Increased-non-SAE, RIGIV, Mod | 0 | 0.012 |
| Blood Pressure Increased-non-SAE, RrHu, Mild | 0 | 0.012 |
| BP Systolic Increased-non-SAE, RIGIV, Mild | 0.011 | 0 |
| Blood Urea Increased-non-SAE, NR, Mild | 0 | 0.012 |
| Body Fat Disorder-non-SAE, NR, Mild | 0 | 0.012 |
| Body Tinea-non-SAE, NR, Mild | 0.011 | 0 |
| Body Tinea-non-SAE, NR, Mod | 0 | 0.012 |
| Bone Pain-non-SAE, NR, Mild | 0 | 0.012 |
| Breast Pain-non-SAE, NR, Mild | 0.011 | 0 |
| Bronchal Hyperreactivity-non-SAE, NR, Mild | 0 | 0.012 |
| Bronchitis-non-SAE, NR, Mild | 0.046 | 0.025 |
| Bronchitis-non-SAE, NR, Mod | 0.023 | 0.099 |
| Bronchitis-SAE, NR, Mod | 0.011 | 0 |
| Bronchospasm-non-SAE, NR, Mod | 0 | 0.012 |
| Burn Infection-non-SAE, NR, Mild | 0 | 0.012 |
| Burning Sensation-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Burning Sensation-non-SAE, RIGIV, Mod | 0 | 0.012 |
| Burning Sensation-non-SAE, RrHu, Mild | 0 | 0.012 |
| Bursitis-non-SAE, NR, Mild | 0.011 | 0 |
| Bursitis-non-SAE, NR, Mod | 0 | 0.012 |
| Candidiasis-non-SAE, NR, Mild | 0.011 | 0 |
| Candidiasis-non-SAE, NR, Mod | 0.011 | 0.012 |
| Cardiac Murmur-non-SAE, NR, Mild | 0 | 0.012 |
| Cellulitis-non-SAE, NR, Mild | 0 | 0.012 |
| Cellulitis-non-SAE, NR, Mod | 0 | 0.037 |
| Cellulitis-non-SAE, Rboth, Mod | 0 | 0.012 |
| Cerumen Impaction-non-SAE, NR, Mild | 0 | 0.025 |
| Cervical Dysplasia-SAE, NR, Mild | 0.011 | 0.012 |
| Cheilitis-non-SAE, NR, Mild | 0.023 | 0 |
| Chest Pain-non-SAE, NR, Mild | 0 | 0.025 |
| Chills-non-SAE, NR, Mild | 0 | 0.037 |
| Chills-non-SAE, RIGIV, Mild | 0.069 | 0.012 |
| Chills-non-SAE, RIGIV, Mod | 0.034 | 0 |
| Chills-non-SAE, Rboth, Mild | 0 | 0.012 |
| COPD-non-SAE, NR, Mod | 0 | 0.025 |
| COPD-non-SAE, NR, Severe | 0.011 | 0 |
| Chronic Sinusitis-non-SAE, NR, Mild | 0 | 0.049 |
| Chronic Sinusitis-non-SAE, NR, Mod | 0.011 | 0.012 |
| Concussion-non-SAE, NR, Mod | 0.011 | 0 |
| Confusional State-non-SAE, NR, Mod | 0 | 0.012 |
| Confusional State-non-SAE, RIGIV, Mild | 0.011 | 0 |
| Conjunctivitis-non-SAE, NR, Mild | 0.011 | 0.025 |
| Conjunctivitis Allergic-non-SAE, NR, Mild | 0.011 | 0 |
| Conjunctivitis Allergic-non-SAE, NR, Mod | 0.011 | 0 |
| Conjunctivitis Bacterial-non-SAE, NR, Mild | 0.011 | 0.012 |
| Conjunctivitis Bacterial-non-SAE, NR, Mod | 0 | 0.012 |
| Conjunctivitis Bacterial-non-SAE, NR, Severe | 0 | 0.012 |
| Constipation-non-SAE, NR, Mild | 0 | 0.037 |
| Contusion-non-SAE, NR, Mild | 0.011 | 0.062 |
| Contusion-non-SAE, NR, Mod | 0.011 | 0 |
| Contusion-non-SAE, RIGIV, Mod | 0 | 0.012 |
| Coombs Test Positive-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Costochondritis-non-SAE, NR, Mod | 0 | 0.012 |
| Cough-non-SAE, NR, Mild | 0.034 | 0.074 |
| Cough-non-SAE, NR, Mod | 0 | 0.025 |
| Cough-non-SAE, RIGIV, Mild | 0.011 | 0 |
| Cushingoid-non-SAE, NR, Mild | 0 | 0.012 |
| Cystitis-non-SAE, NR, Mild | 0 | 0.012 |
| Deafness Neurosensory-non-SAE, NR, Mild | 0.011 | 0 |
| Decreased Appetite-non-SAE, NR, Mild | 0.011 | 0.012 |
| Decreased Appetite-non-SAE, RrHu, Mild | 0 | 0.012 |
| Decreased Appetite-non-SAE, Rboth, Mild | 0 | 0.025 |
| Dehydration-non-SAE, NR, Mod | 0 | 0.025 |
| Dental Caries-non-SAE, NR, Mild | 0 | 0.025 |
| Dental Caries-non-SAE, NR, Mod | 0 | 0.037 |
| Depressed Mood-non-SAE, NR, Mild | 0 | 0.012 |
| Depression-non-SAE, NR, Severe | 0 | 0.012 |
| Dermal Cyst-non-SAE, NR, Mild | 0 | 0.012 |
| Dermatitis-non-SAE, NR, Mild | 0 | 0.025 |
| Dermatitis-non-SAE, NR, Mod | 0.011 | 0 |
| Dermatitis Acneiform-non-SAE, NR, Mod | 0.011 | 0 |
| Dermatitis Contact-non-SAE, NR, Mild | 0 | 0.025 |
| Dermatitis Contact-non-SAE, NR, Mod | 0.023 | 0.025 |
| Dermatitis Infected-non-SAE, NR, Mild | 0 | 0.025 |
| Dermatitis Infected-non-SAE, NR, Mod | 0 | 0.012 |
| Dermatitis Infected-non-SAE, NR, Severe | 0 | 0.012 |
| Device Failure-non-SAE, NR, Mild | 0.023 | 0.012 |
| Device Failure-non-SAE, NR, Mod | 0 | 0.025 |
| Diarrhoea-non-SAE, NR, Mild | 0.034 | 0.074 |
| Diarrhoea-non-SAE, NR, Mod | 0.023 | 0.049 |
| Diarrhoea-non-SAE, RIGIV, Mild | 0.011 | 0.012 |
| Diarrhoea-non-SAE, RIGIV, Mod | 0.011 | 0 |
| Diarrhoea Haemorrhagic-non-SAE, NR, Mild | 0.011 | 0 |
| Diarrhoea Infectious-non-SAE, NR, Mild | 0 | 0.012 |
| Diastolic Dysfunction-non-SAE, NR, Mild | 0 | 0.012 |
| Disaccharide Metabolism Disorder-non-SAE, NR, Mild | 0 | 0.012 |
| Disturbance in Attention-non-SAE, NR, Mild | 0 | 0.025 |
| Diverticulitis-non-SAE, NR, Mod | 0.011 | 0 |
| Dizziness-non-SAE, NR, Mild | 0.023 | 0.086 |
| Dizziness-non-SAE, NR, Mod | 0 | 0.025 |
| Dizziness-non-SAE, RIGIV, Mild | 0 | 0.037 |
| Dizziness-non-SAE, RIGIV, Mod | 0.011 | 0 |
| Drug Eruption-non-SAE, NR, Mod | 0.011 | 0 |
| Dry Eye-non-SAE, NR, Mod | 0 | 0.012 |
| Dry Mouth-non-SAE, NR, Mild | 0 | 0.012 |
| Dry Skin-non-SAE, NR, Mild | 0 | 0.037 |
| Dysmenorrhoea-non-SAE, NR, Mild | 0 | 0.012 |
| Dyspepsia-non-SAE, NR, Mild | 0 | 0.025 |
| Dyspepsia-non-SAE, NR, Mod | 0 | 0.012 |
| Dyspepsia-non-SAE, RIGIV, Mild | 0.011 | 0 |
| Dysphagia-non-SAE, NR, Mild | 0 | 0.012 |
| Dysphagia-non-SAE, NR, Mod | 0 | 0.012 |
| Dyspnoea-non-SAE, NR, Mild | 0.011 | 0 |
| Dyspnoea-non-SAE, NR, Mod | 0.011 | 0 |
| Dyspnoea-non-SAE, RIGIV, Mild | 0.011 | 0 |
| Dysuria-non-SAE, NR, Mild | 0 | 0.025 |
| Ear Infection-non-SAE, NR, Mild | 0.023 | 0.025 |
| Ear Infection-non-SAE, NR, Mod | 0.011 | 0.012 |
| Ear Pain-non-SAE, NR, Mild | 0.034 | 0.025 |
| Ear Pain-non-SAE, NR, Mod | 0 | 0.012 |
| Ecchymosis-non-SAE, NR, Mild | 0 | 0.012 |
| Eczema-non-SAE, NR, Mild | 0 | 0.012 |
| Eczema-non-SAE, NR, Mod | 0 | 0.012 |
| Eczema-non-SAE, NR, Severe | 0.011 | 0 |
| Eosinophil Count-non-SAE, NR, Mild | 0 | 0.012 |
| Epitaxis-non-SAE, NR, Mild | 0.023 | 0.037 |
| Epitaxis-non-SAE, NR, Mod | 0.023 | 0.025 |
| Erythema-non-SAE, NR, Mild | 0.011 | 0 |
| Erythema-non-SAE, RIGIV, Mod | 0 | 0.012 |
| Erythema-non-SAE, RrHu, Mild | 0 | 0.012 |
| Erythema-non-SAE, Rboth, Mild | 0 | 0.012 |
| Erythema-non-SAE, Rboth, Mod | 0 | 0.012 |
| Eustachian Tube Dysfunction-non-SAE, NR, Mild | 0.011 | 0 |
| Excoriation-non-SAE, NR, Mild | 0.025 | 0.025 |
| Extravasation Blood-non-SAE, Rboth, Mild | 0 | 0.012 |
| Eye Irritation-non-SAE, NR, Mild | 0 | 0.012 |
| Eye Pruritus-non-SAE, NR, Mod | 0 | 0.012 |
| Eye Swelling-non-SAE, NR, Mod | 0 | 0.012 |
| Fall-non-SAE, NR, Mild | 0 | 0.012 |
| Fall-non-SAE, NR, Mod | 0 | 0.012 |
| Fatigue-non-SAE, NR, Mild | 0.011 | 0.062 |
| Fatigue-non-SAE, NR, Mod | 0.011 | 0.025 |
| Fatigue-non-SAE, RIGIV, Mild | 0.092 | 0.099 |
| Fatigue-non-SAE, RIGIV, Mod | 0 | 0.037 |
| Fatigue-non-SAE, Rboth, Mild | 0 | 0.037 |
| Feeling Abnormal-non-SAE, Rboth, Mod | 0 | 0.012 |
| Feeling Cold-non-SAE, RIGIV, Mild | 0.023 | 0 |
| Flatulence-non-SAE, NR, Mild | 0 | 0.012 |
| Flatulence-non-SAE, NR, Mod | 0 | 0.012 |
| Food Poisoning-non-SAE, NR, Mod | 0 | 0.012 |
| Free Haemoglobin Present-non-SAE, NR, Mild | 0.011 | 0.012 |
| Free Haemoglobin Present-non-SAE, NR, Severe | 0.011 | 0 |
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe
| Number of AEs per participant | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Gait Disturbance-non-SAE, NR, Mild | 0 | 0.012 |
| Gastroenteritis-non-SAE, NR, Mild | 0 | 0.037 |
| Gastroenteritis-non-SAE, NR, Mod | 0.023 | 0.025 |
| Gastroenteritis-non-SAE, RIGIV, Mild | 0.011 | 0 |
| Gastroenteritis-SAE, NR, Mod | 0 | 0.012 |
| Gastroenteritis Bacterial-non-SAE, NR, Mod | 0 | 0.012 |
| Gastroenteritis Viral-non-SAE, NR, Mild | 0.034 | 0.074 |
| Gastroenteritis Viral-non-SAE, NR, Mod | 0 | 0.062 |
| Gastroenteritis Viral-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Gastrointestinal Haemorrhage-non-SAE, NR, Severe | 0 | 0.012 |
| Gastrooesophageal Reflux Disease-non-SAE, NR, Mild | 0.011 | 0.025 |
| Gastrooesophageal Reflux Disease-non-SAE, NR, Mod | 0.011 | 0 |
| Genital Herpes-non-SAE, NR, Mild | 0.011 | 0 |
| Genital Swelling-non-SAE, Rboth, Mod | 0 | 0.012 |
| Goitre-non-SAE, NR, Mild | 0.011 | 0 |
| Gout-non-SAE, NR, Mild | 0 | 0.012 |
| Grand Mal Convulsion-non-SAE, NR, Severe | 0.011 | 0 |
| Grand Mal Convulsion-SAE, NR, Severe | 0 | 0.012 |
| Gravitational Oedema-non-SAE, Rboth, Mod | 0 | 0.012 |
| Groin Pain-non-SAE, NR, Mild | 0 | 0.012 |
| Groin Pain-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Groin Pain-non-SAE, RrHu, Mod | 0 | 0.012 |
| Haematoma-non-SAE, NR, Mild | 0.011 | 0.012 |
| Haematoma-non-SAE, NR, Mod | 0 | 0.012 |
| Haematuria-non-SAE, NR, Mild | 0 | 0.012 |
| Haemoglobin Abnormal-non-SAE, NR, Mild | 0 | 0.012 |
| Haemorrhoids-non-SAE, NR, Mild | 0 | 0.025 |
| Hand Fracture-non-SAE, NR, Mod | 0 | 0.012 |
| Headache-non-SAE, NR, Mild | 0.149 | 0.198 |
| Headache-non-SAE, NR, Mod | 0.011 | 0.037 |
| Headache-non-SAE, NR, Severe | 0.011 | 0 |
| Headache-non-SAE, RIGIV, Mild | 0.287 | 0.173 |
| Headache-non-SAE, RIGIV, Mod | 0.138 | 0.062 |
| Headache-non-SAE, RIGIV, Severe | 0.011 | 0 |
| Headache-non-SAE, Rboth, Mild | 0 | 0.011 |
| Headache-non-SAE, Rboth, Mod | 0 | 0.099 |
| Headache-SAE, NR, Severe | 0 | 0.012 |
| Hearing Impaired-non-SAE, NR, Mild | 0 | 0.012 |
| Heart Rate Increased-non-SAE, RIGIV, Mild | 0.046 | 0 |
| Heat Rash-non-SAE, NR, Mild | 0 | 0.012 |
| Heat Stroke-non-SAE, NR, Mod | 0 | 0.012 |
| Herpes Simplex Ophthalmic-non-SAE, NR, Mod | 0 | 0.012 |
| Herpes Zoster-non-SAE, NR, Mod | 0 | 0.012 |
| Hiatus Hernia-non-SAE, NR, Mod | 0 | 0.012 |
| Hot Flush-non-SAE, RIGIV, Mild | 0.011 | 0 |
| Hyperaesthesia-non-SAE, NR, Mild | 0 | 0.012 |
| Hypercholesterolaemia-non-SAE, NR, Mod | 0 | 0.012 |
| Hyperkeratosis-non-SAE, NR, Mild | 0 | 0.012 |
| Hypertension-non-SAE, NR, Mod | 0 | 0.049 |
| Hypertension-non-SAE, RIGIV, Mild | 0 | 0.025 |
| Hypertension-non-SAE, RIGIV, Mod | 0 | 0.012 |
| Hypertonia-non-SAE, NR, Mild | 0 | 0.012 |
| Hypothyroidism-non-SAE, NR, Mild | 0 | 0.012 |
| Idiopathic Urticaria-non-SAE, NR, Mod | 0.011 | 0 |
| Increased Upper Airway Secretion-non-SAE, NR, Mild | 0.023 | 0 |
| Infected Bites-non-SAE, NR, Mild | 0 | 0.025 |
| Infected Bites-non-SAE, NR, Mod | 0.011 | 0.012 |
| Infection-non-SAE, NR, Mod | 0 | 0.025 |
| Influenza-non-SAE, NR, Mild | 0.011 | 0.025 |
| Influenza-non-SAE, NR, Mod | 0.046 | 0.037 |
| Influenza Like Illness-non-SAE, NR, Mild | 0 | 0.012 |
| Infusion Related Reaction-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Infusion Related Reaction-non-SAE, RIGIV, Mod | 0.011 | 0 |
| Infusion Related Reaction-non-SAE, Rboth, Mild | 0 | 0.012 |
| Infusion Related Reaction-non-SAE, Rboth, Mod | 0 | 0.012 |
| Infusion Site Discomfort-non-SAE, RIGIV, Mild | 0 | 0.074 |
| Infusion Site Discomfort-non-SAE, RrHu, Mod | 0 | 0.012 |
| Infusion Site Discomfort-non-SAE, Rboth, Mild | 0 | 0.185 |
| Infusion Site Discomfort-non-SAE, Rboth, Mod | 0 | 0.099 |
| Infusion Site Erythema-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Infusion Site Erythema-non-SAE, RrHu, Mild | 0 | 0.025 |
| Infusion Site Erythema-non-SAE, Rboth, Mild | 0 | 0.247 |
| Infusion Site Erythema-non-SAE, Rboth, Mod | 0 | 0.062 |
| Infusion Site Extravasation-non-SAE, NR, Mild | 0.023 | 0 |
| Infusion Site Haematoma-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Infusion Site Haemorrhage-non-SAE, Rboth, Mild | 0 | 0.012 |
| Infusion Site Hypersensitivity-non-SAE, NR, Severe | 0 | 0.012 |
| Infusion Site Hypersensitivity-non-SAE, Rboth, Mod | 0 | 0.012 |
| Infusion Site Mass-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Infusion Site Mass-non-SAE, Rboth, Mild | 0 | 0.025 |
| Infusion Site Oedema-non-SAE, Rboth, Mild | 0 | 0.049 |
| Infusion Site Oedema-non-SAE, Rboth, Mod | 0 | 0.062 |
| Infusion Site Pain-non-SAE, NR, Mild | 0 | 0.025 |
| Infusion Site Pain-non-SAE, RIGIV, Mild | 0.011 | 0.148 |
| Infusion Site Pain-non-SAE, RIGIV, Mod | 0 | 0.074 |
| Infusion Site Pain-non-SAE, RrHu, Mild | 0 | 0.432 |
| Infusion Site Pain-non-SAE, RrHu, Mod | 0 | 0.012 |
| Infusion Site Pain-non-SAE, Rboth, Mild | 0 | 0.235 |
| Infusion Site Pain-non-SAE, Rboth, Mod | 0 | 0.198 |
| Infusion Site Pain-non-SAE, Rboth, Severe | 0 | 0.012 |
| Infusion Site Pruritus-non-SAE, RIGIV, Mild | 0 | 0.025 |
| Infusion Site Pruritus-non-SAE, RrHu, Mild | 0 | 0.062 |
| Infusion Site Pruritus-non-SAE, Rboth, Mild | 0 | 0.074 |
| Infusion Site Pruritus-non-SAE, Rboth, Mod | 0 | 0.049 |
| Infusion Site Reaction-non-SAE, Rboth, Mild | 0 | 0.012 |
| Infusion Site Reaction-non-SAE, Rboth, Mod | 0 | 0.025 |
| Infusion Site Swelling-non-SAE, RIGIV, Mild | 0 | 0.025 |
| Infusion Site Swelling-non-SAE, Rboth, Mild | 0 | 0.037 |
| Infusion Site Swelling-non-SAE, Rboth, Mod | 0 | 0.049 |
| Infusion Site Swelling-non-SAE, Rboth, Severe | 0 | 0.012 |
| Infusion Site Warmth-non-SAE, Rboth, Mild | 0 | 0.025 |
| Ingrowing Nail-non-SAE, NR, Mod | 0 | 0.012 |
| Injection Site Erythema-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Injury-non-SAE, NR, Mild | 0.011 | 0 |
| Insomnia-non-SAE, NR, Mild | 0.011 | 0 |
| Intervertebral Disc Protrusion-non-SAE, NR, Mod | 0.011 | 0 |
| Irritable Bowel Syndrome-non-SAE, NR, Mild | 0 | 0.012 |
| Irritable Bowel Syndrome-non-SAE, NR, Mod | 0 | 0.025 |
| Joint Effusion-non-SAE, NR, Mild | 0 | 0.012 |
| Joint Effusion-non-SAE, NR, Mod | 0 | 0.012 |
| Joint Injury-non-SAE, NR, Mod | 0.011 | 0.012 |
| Joint Range of Motion Decreased-non-SAE, NR, Mod | 0 | 0.025 |
| Joint Sprain-non-SAE, NR, Mild | 0 | 0.012 |
| Joint Sprain-non-SAE, NR, Mod | 0 | 0.025 |
| Joint Swelling-non-SAE, NR, Mild | 0 | 0.012 |
| Jugular Vein Distension-non-SAE, NR, Mild | 0 | 0.012 |
| Lethargy-non-SAE, NR, Mild | 0 | 0.012 |
| Lethargy-non-SAE, RIGIV, Mod | 0 | 0.011 |
| Ligament Injury-non-SAE, NR, Mod | 0 | 0.012 |
| Ligament Sprain-non-SAE, NR, Mod | 0 | 0.012 |
| Limb Injury-non-SAE, NR, Mild | 0.011 | 0 |
| Lip Injury-non-SAE, NR, Mild | 0 | 0.012 |
| Lip Ulceration-non-SAE, NR, Mild | 0 | 0.012 |
| Local Swelling-non-SAE, RIGIV, Mild | 0 | 0.037 |
| Local Swelling-non-SAE, Rboth, Mild | 0 | 0.037 |
| Localised Infection-non-SAE, NR, Mild | 0 | 0.012 |
| Localised Oedema-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Localised Oedema-non-SAE, Rboth, Mod | 0 | 0.012 |
| Lung Infection-non-SAE, NR, Mod | 0.011 | 0 |
| Lung Infection-non-SAE, NR, Severe | 0.011 | 0 |
| Lymph Gland Infection-non-SAE, NR, Mod | 0.011 | 0 |
| Lymph Node Pain-non-SAE, NR, Mild | 0.011 | 0 |
| Lymph Node Pain-non-SAE, NR, Mod | 0 | 0.012 |
| Lymph Node Palpable-non-SAE, NR, Mild | 0.011 | 0 |
| Lymphadenitis-non-SAE, NR, Mod | 0.011 | 0 |
| Lymphadenopathy-non-SAE, NR, Mild | 0.023 | 0.099 |
| Lymphangitis-non-SAE, NR, Mod | 0 | 0.012 |
| Lymphocyte Count Decreased-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Lymphoedema-non-SAE, NR, Severe | 0.011 | 0 |
| Malaise-non-SAE, NR, Mild | 0 | 0.025 |
| Malaise-non-SAE, NR, Mod | 0 | 0.012 |
| Malaise-non-SAE, RIGIV, Mod | 0.011 | 0 |
| Malaise-non-SAE, RrHu, Mild | 0 | 0.012 |
| Malaise-non-SAE, RrHu, Mod | 0 | 0.012 |
| Memory Impairment-non-SAE, NR, Mod | 0 | 0.012 |
| Migraine-non-SAE, NR, Mild | 0.011 | 0.012 |
| Migraine-non-SAE, NR, Mod | 0 | 0.025 |
| Migraine-non-SAE, NR, Severe | 0.011 | 0 |
| Migraine-non-SAE, RIGIV, Mild | 0.011 | 0.012 |
| Migraine-non-SAE, RIGIV, Mod | 0.011 | 0.049 |
| Migraine-non-SAE, RIGIV, Severe | 0 | 0.012 |
| Migraine-non-SAE, Rboth, Mod | 0 | 0.012 |
| Molluscum Contagiosum-non-SAE, NR, Mild | 0.023 | 0 |
| Mouth Ulceration-non-SAE, NR, Mild | 0.011 | 0 |
| Multiple Sclerosis Relapse-non-SAE, NR, Mod | 0 | 0.012 |
| Muscle Fatigue-non-SAE, NR, Mild | 0 | 0.012 |
| Muscle Injury-non-SAE, NR, Mild | 0 | 0.025 |
| Muscle Spasms-non-SAE, NR, Mild | 0 | 0.012 |
| Muscle Spasms-non-SAE, RIGIV, Mild | 0.011 | 0 |
| Muscle Strain-non-SAE, NR, Mild | 0.011 | 0.012 |
| Muscle Strain-non-SAE, NR, Mod | 0 | 0.012 |
| Muscular Weakness-non-SAE, NR, Mild | 0.011 | 0 |
| Musculoskeletal Chest Pain-non-SAE, NR, Mild | 0 | 0.012 |
| Musculoskeletal Chest Pain-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Musculoskeletal Pain-non-SAE, NR, Mild | 0.023 | 0 |
| Musculoskeletal Pain-non-SAE, NR, Mod | 0.011 | 0.012 |
| Musculoskeletal Stiffness-non-SAE, NR, Mild | 0.011 | 0.012 |
| Myalgia-non-SAE, NR, Mild | 0.034 | 0.062 |
| Myalgia-non-SAE, NR, Mod | 0.011 | 0.049 |
| Myalgia-non-SAE, NR, Severe | 0 | 0.012 |
| Myalgia-non-SAE, RIGIV, Mild | 0 | 0.074 |
| Myalgia-non-SAE, RIGIV, Mod | 0.011 | 0.012 |
| Myalgia-non-SAE, Rboth, Mild | 0 | 0.037 |
Categories presented as Preferred term-Seriousness, Relatedness, Severity. The following codes are to be used: Seriousness: non-SAE-non-serious AE; SAE-serious AE Relationship: NR-not related to immune globulin (IGIV), 10% and recombinant human hyaluronidase (rHuPH20); RIGIV-related to IGIV, 10%; RrHu-related to rHuPH20; Rboth-related to both IGIV, 10% and rHuPH20 Severity: Mild; Mod (Moderate); Severe Preferred terms abbreviated: Resp.-Respiratory WBC - White blood cells
| Number of AEs per participant | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Nasal Congestion-non-SAE, NR, Mild | 0.046 | 0.037 |
| Nasal Congestion-non-SAE, NR, Mod | 0 | 0.025 |
| Nasal Congestion-non-SAE, RIGIV, Mild | 0 | 0.037 |
| Nasal Discomfort-non-SAE, NR, Mild | 0 | 0.012 |
| Nasal Mucosal Discolouration-non-SAE, NR, Mild | 0 | 0.012 |
| Nasal Turbinate Hypertrophy-non-SAE, NR, Mild | 0 | 0.012 |
| Nasopharyngitis-non-SAE, NR, Mild | 0.046 | 0.099 |
| Nausea-non-SAE, NR, Mild | 0.034 | 0.210 |
| Nausea-non-SAE, NR, Mod | 0.023 | 0.037 |
| Nausea-non-SAE, RIGIV, Mild | 0.080 | 0.012 |
| Nausea-non-SAE, RIGIV, Mod | 0.011 | 0 |
| Nausea-non-SAE, Rboth, Mild | 0 | 0.049 |
| Neck Pain-non-SAE, NR, Mild | 0.011 | 0.012 |
| Night Sweats-non-SAE, NR, Mild | 0.011 | 0 |
| Night Sweats-non-SAE, NR, Mod | 0 | 0.012 |
| Nodule-non-SAE, Rboth, Mild | 0 | 0.025 |
| Oedema-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Oedema Genital-non-SAE, Rboth, Severe | 0 | 0.012 |
| Oedema Peripheral-non-SAE, NR, Mild | 0 | 0.012 |
| Oedema Peripheral-non-SAE, NR, Mod | 0 | 0.012 |
| Oedema Peripheral-non-SAE, Rboth, Mod | 0 | 0.025 |
| Oesophagitis-non-SAE, NR, Mild | 0 | 0.012 |
| Onychomycosis-non-SAE, NR, Mild | 0 | 0.012 |
| Oral Candidiasis-non-SAE, NR, Mod | 0 | 0.012 |
| Oral Fungal Infection-non-SAE, NR, Mild | 0 | 0.012 |
| Oral Herpes-non-SAE, NR, Mild | 0.011 | 0.025 |
| Oral Herpes-non-SAE, NR, Mod | 0 | 0.012 |
| Oral Pain-non-SAE, NR, Mild | 0 | 0.012 |
| Oral Pain-non-SAE, RrHu, Severe | 0 | 0.012 |
| Oropharyngeal Pain-non-SAE, NR, Mild | 0.011 | 0.049 |
| Oropharyngeal Pain-non-SAE, NR, Mod | 0.023 | 0.012 |
| Osteoarthritis-non-SAE, NR, Mod | 0 | 0.012 |
| Osteopenia-non-SAE, NR, Mild | 0 | 0.012 |
| Osteopenia-non-SAE, NR, Mod | 0 | 0.012 |
| Osteoporosis-non-SAE, NR, Mild | 0 | 0.012 |
| Otitis Externa-non-SAE, NR, Mild | 0 | 0.012 |
| Otitis Externa-non-SAE, NR, Mod | 0 | 0.012 |
| Otitis Media-non-SAE, NR, Mod | 0.011 | 0.012 |
| Pain-non-SAE, NR, Mild | 0.011 | 0.062 |
| Pain-non-SAE, NR, Mod | 0.011 | 0.012 |
| Pain-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Pain-non-SAE, RIGIV, Mod | 0.023 | 0.012 |
| Pain-non-SAE, Rboth, Mild | 0 | 0.012 |
| Pain-non-SAE, Rboth, Mod | 0 | 0.012 |
| Pain in Extremity-non-SAE, NR, Mild | 0.023 | 0.012 |
| Pain in Extremity-non-SAE, NR, Mod | 0.011 | 0.025 |
| Pain in Extremity-non-SAE, RIGIV, Mod | 0.023 | 0 |
| Pain in Extremity-non-SAE, RIGIV, Severe | 0.011 | 0 |
| Pain in Extremity-non-SAE, Rboth, Mild | 0 | 0.037 |
| Pain in Extremity-non-SAE, Rboth, Mod | 0 | 0.025 |
| Palpitations-non-SAE, NR, Mild | 0.011 | 0.012 |
| Papule-non-SAE, NR, Mild | 0 | 0.012 |
| Peptic Ulcer Haemorrhage-SAE, NR, Severe | 0.011 | 0 |
| Periorbital Haematoma-non-SAE, NR, Mild | 0 | 0.012 |
| Peripheral Nerve Injury-non-SAE, NR, Mild | 0 | 0.012 |
| Pertussis-non-SAE, NR, Mod | 0 | 0.012 |
| Petit Mal Epilepsy-SAE, NR, Severe | 0 | 0.012 |
| Pharyngeal Erythema-non-SAE, NR, Mild | 0.011 | 0.037 |
| Pharyngitis-non-SAE, NR, Mild | 0.011 | 0.049 |
| Pharyngitis-non-SAE, NR, Mod | 0.011 | 0 |
| Pharyngitis Streptococcal-non-SAE, NR, Mod | 0 | 0.049 |
| Pneumonia-non-SAE, NR, Mild | 0 | 0.012 |
| Pneumonia-non-SAE, NR, Mod | 0 | 0.012 |
| Pneumonia Bacterial-non-SAE, NR, Mod | 0 | 0.012 |
| Post Procedural Infection-non-SAE, NR, Mild | 0.011 | 0.025 |
| Post Procedural Infection-non-SAE, NR, Mod | 0 | 0.062 |
| Postictal Paralysis-non-SAE, NR, Mod | 0 | 0.012 |
| Postoperative Wound Infection-non-SAE, NR, Mod | 0 | 0.012 |
| Procedural Pain-non-SAE, NR, Mild | 0 | 0.025 |
| Procedural Pain-non-SAE, NR, Mod | 0 | 0.012 |
| Productive Cough-non-SAE, NR, Mild | 0.011 | 0.012 |
| Pruritus-non-SAE, NR, Mild | 0.011 | 0 |
| Pruritus-non-SAE, RIGIV, Mild | 0.011 | 0 |
| Pruritus-non-SAE, Rboth, Mild | 0 | 0.012 |
| Pruritus-non-SAE, Rboth, Mod | 0 | 0.012 |
| Pruritus Generalized-non-SAE, NR, Mild | 0.011 | 0 |
| Pseudomonas Infection-non-SAE, NR, Mod | 0 | 0.012 |
| Psoriasis-non-SAE, NR, Mod | 0 | 0.012 |
| Pyrexia-non-SAE, NR, Mild | 0.034 | 0.136 |
| Pyrexia-non-SAE, NR, Mod | 0.023 | 0.012 |
| Pyrexia-non-SAE, RIGIV, Mild | 0.046 | 0.074 |
| Pyrexia-non-SAE, RIGIV, Mod | 0.023 | 0.025 |
| Pyrexia-non-SAE, Rboth, Mild | 0 | 0.025 |
| Rales-non-SAE, NR, Mild | 0 | 0.012 |
| Rales-non-SAE, NR, Mod | 0 | 0.012 |
| Rash-non-SAE, NR, Mild | 0.023 | 0.062 |
| Rash-non-SAE, NR, Mod | 0 | 0.012 |
| Rash Erythematous-non-SAE, NR, Mild | 0 | 0.012 |
| Rash Maculo-Papular-non-SAE, Rboth, Mild | 0 | 0.012 |
| Rash Pustular-non-SAE, NR, Mild | 0 | 0.012 |
| Rash Pustular-non-SAE, NR, Mod | 0.011 | 0 |
| Rash Papular-non-SAE, NR, Mild | 0 | 0.012 |
| Respiratory Failure-SAE, NR, Severe | 0 | 0.012 |
| Respiratory Rate Increased-non-SAE, NR, Mild | 0 | 0.012 |
| Respiratory Tract Congestion-non-SAE, NR, Mild | 0 | 0.012 |
| Respiratory Tract Infection-non-SAE, NR, Mild | 0.011 | 0.012 |
| Respiratory Tract Infection-non-SAE, NR, Mod | 0.011 | 0.037 |
| Respiratory Tract Infection Viral-non-SAE, NR, Mod | 0.011 | 0 |
| Rhinitis Allergic-non-SAE, NR, Mild | 0.011 | 0.037 |
| Rhinitis Allergic-non-SAE, NR, Mod | 0.034 | 0.012 |
| Rhinitis Allergic-non-SAE, RIGIV, Mod | 0.011 | 0 |
| Rhinorrhoea-non-SAE, NR, Mild | 0.011 | 0.012 |
| Road Traffic Accident-non-SAE, NR, Mod | 0 | 0.025 |
| Scleritis-non-SAE, NR, Mild | 0.011 | 0.012 |
| Scleritis-non-SAE, NR, Mod | 0 | 0.012 |
| Scratch-non-SAE, NR, Mild | 0.011 | 0 |
| Seborrhoeic Dermatitis-non-SAE, NR, Mild | 0 | 0.012 |
| Sicca Syndrome-non-SAE, NR, Mod | 0 | 0.012 |
| Sinus Congestion-non-SAE, NR, Mild | 0.011 | 0 |
| Sinus Headache-non-SAE, NR, Mild | 0.011 | 0 |
| Sinusitis-non-SAE, NR, Mild | 0.069 | 0.309 |
| Sinusitis-non-SAE, NR, Mod | 0.149 | 0.321 |
| Sinusitis-non-SAE, NR, Severe | 0 | 0.012 |
| Sinusitis-non-SAE, RIGIV, Mod | 0 | 0.012 |
| Skeletal Injury-non-SAE, NR, Mild | 0 | 0.012 |
| Skeletal Injury-non-SAE, NR, Mod | 0 | 0.012 |
| Skin Hyperpigmentation-non-SAE, Rboth, Mild | 0 | 0.012 |
| Skin Laceration-non-SAE, NR, Mild | 0 | 0.012 |
| Skin Laceration-non-SAE, NR, Mod | 0 | 0.012 |
| Skin Lesion-non-SAE, NR, Mild | 0.023 | 0.012 |
| Skin Lesion-non-SAE, NR, Mod | 0.011 | 0 |
| Skin Lesion-non-SAE, RIGIV, Mild | 0 | 0.025 |
| Skin Papilloma-non-SAE, NR, Mod | 0.011 | 0 |
| Spinal Osteoarthritis-non-SAE, NR, Mild | 0 | 0.025 |
| Squamous Cell Carcinoma-non-SAE, NR, Mod | 0.011 | 0.012 |
| Status Epilepticus-SAE, NR, Severe | 0 | 0.012 |
| Suicidal Ideation-non-SAE, NR, Mild | 0.011 | 0 |
| Sunburn-non-SAE, NR, Mild | 0 | 0.012 |
| Swelling-non-SAE, Rboth, Mild | 0 | 0.012 |
| Swelling-non-SAE, Rboth, Mod | 0 | 0.037 |
| Syncope-non-SAE, NR, Mild | 0 | 0.012 |
| Tachycardia-non-SAE, NR, Mild | 0.037 | 0 |
| Tachycardia-non-SAE, NR, Mod | 0 | 0.012 |
| Therapy Cessation-non-SAE, NR, Severe | 0 | 0.012 |
| Thrombosis-non-SAE, NR, Severe | 0 | 0.012 |
| Thrombosis-SAE, NR, Mod | 0 | 0.012 |
| Tinea Infection-non-SAE, NR, Mild | 0 | 0.023 |
| Tongue Coated-non-SAE, NR, Mild | 0 | 0.012 |
| Tonsillar Hypertrophy-non-SAE, NR, Mod | 0 | 0.012 |
| Tonsillar Hypertrophy-SAE, NR, Mild | 0 | 0.012 |
| Tooth Abscess-non-SAE, NR, Mild | 0.011 | 0 |
| Tooth Abscess-non-SAE, NR, Mod | 0 | 0.012 |
| Tooth Impacted-non-SAE, NR, Mod | 0 | 0.012 |
| Tooth Infection-non-SAE, NR, Mod | 0 | 0.012 |
| Toothache-non-SAE, NR, Mod | 0 | 0.012 |
| Tongue Injury-non-SAE, NR, Mild | 0 | 0.012 |
| Tremor-non-SAE, NR, Mild | 0 | 0.012 |
| Tricuspid Valve Incompetence-non-SAE, NR, Mild | 0 | 0.012 |
| Tympanic Membrane Disorder-non-SAE, NR, Mild | 0.011 | 0 |
| Tympanic Membrane Hyperaemia-non-SAE, NR, Mild | 0 | 0.025 |
| Upper Airway Cough Syndrome-non-SAE, NR, Mild | 0 | 0.012 |
| Upper Resp. Tract Infection-non-SAE, NR, Mild | 0.080 | 0.420 |
| Upper Resp. Tract Infection-non-SAE, NR, Mod | 0.023 | 0.123 |
| Urinary Tract Infection-non-SAE, NR, Mild | 0.011 | 0.025 |
| Urinary Tract Infection-non-SAE, NR, Mod | 0.057 | 0.049 |
| Urine Analysis Abnormal-non-SAE, NR, Mild | 0 | 0.012 |
| Urticaria-non-SAE, NR, Mild | 0 | 0.062 |
| Urticaria-non-SAE, NR, Mod | 0 | 0.012 |
| Urticaria-non-SAE, RIGIV, Mild | 0.011 | 0 |
| Uterine Polyp-non-SAE, NR, Mod | 0 | 0.012 |
| Vaginal Haemorrhage-non-SAE, NR, Mod | 0 | 0.012 |
| Vascular Access Complication-non-SAE, NR, Mild | 0.011 | 0 |
| Vertigo-non-SAE, NR, Mod | 0 | 0.012 |
| Viral Diarrhoea-non-SAE, NR, Mild | 0 | 0.012 |
| Viral Infection-non-SAE, NR, Mild | 0.034 | 0.086 |
| Viral Infection-non-SAE, NR, Mod | 0.034 | 0.037 |
| Viral Infection-SAE, NR, Mild | 0.011 | 0 |
| Viral Upper Resp. Tract Infection-non-SAE, NR Mild | 0.011 | 0.099 |
| Viral Upper Resp. Tract Infection-non-SAE, NR, Mod | 0.011 | 0.012 |
| Vision Blurred-non-SAE, NR, Mild | 0 | 0.012 |
| Vitamin D Deficiency-non-SAE, NR, Mild | 0.011 | 0 |
| Vitamin D Deficiency-non-SAE, NR, Mod | 0 | 0.025 |
| Vomiting-non-SAE, NR, Mild | 0.057 | 0.096 |
| Vomiting-non-SAE, NR, Mod | 0 | 0.037 |
| Vomiting-non-SAE, RIGIV, Mild | 0.046 | 0.037 |
| Vomiting-non-SAE, RIGIV, Mod | 0.011 | 0.049 |
| Vomiting-non-SAE, RIGIV, Severe | 0.011 | 0 |
| Vomiting-non-SAE, Rboth, Mod | 0 | 0.012 |
| Vulvovaginal Pruritus-non-SAE, RIGIV, Mild | 0 | 0.012 |
| Weight Decreased-non-SAE, RrHu, Mild | 0 | 0.012 |
| Weight Decreased-non-SAE, RrHu, Mod | 0 | 0.012 |
| Wheezing-non-SAE, NR, Mod | 0 | 0.012 |
| WBC Count Decreased-non-SAE, RIGIV, Mild | 0 | 0.012 |
| White Blood Cells Urine Positive-non-SAE, NR, Mild | 0 | 0.012 |
| WBC Urine Positive-non-SAE, RIGIV Mild | 0.011 | 0 |
Percentage of Infusions Associated With ≥1 AE Related to immune globulin intravenous (IGIV), 10%, \[administered via intravenous (IV) or subcutaneous (SC) route\], recombinant human hyaluronidase (rHuPH20) or both. The percentage of affected infusions is calculated per subject and then summarized by the median of all subjects analysed.
| Percentage of infusions | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 With Ramp-up |
|---|---|---|
| Including infections | 0.0 (0.0 to 25.0) | 8.3 (6.3 to 20.8) |
| Excluding infections | 0.0 (0.0 to 25.0) | 8.3 (6.3 to 20.8) |
Epoch 2: subcutaneous (SC) administration of immune globulin intravenous (IGIV), 10% with recombinant human hyaluronidase (rHuPH20) after ramp-up. Dose used in Epoch 2 (after ramp-up) was 108% of dose used in intravenous (IV) administration of IGIV, 10%. The percentage of affected infusions is calculated per subject and then summarized by the median of all subjects analysed.
| Percentage of infusions | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Percentage of Infusions Tolerated With IV and SC Administration at Dose Used in Study Epoch 2 (SC/rHuPH20 Treatment) | 100.0 (100.0 to 100.0) | 100.0 (100.0 to 100.0) |
Temporally associated defined as during infusion or within 72 hours of completion of infusion. Related defined as determined by investigator to be at least possibly related to study drug (immune globulin intravenous \[IGIV\], 10% or recombinant human hyaluronidase \[rHuPH20\]). Expressed as a percentage.
| Percentage of AE | IV Administration of IGIV, 10% | SC Administration of IGIV, 10% With rHuPH20 After Ramp-up |
|---|---|---|
| Including Infections | 0.25 (0.25 to 0.50) | 0.22 (0.13 to 0.31) |
| Excluding Infections | 0.25 (0.20 to 0.50) | 0.18 (0.12 to 0.26) |
| Number of participants | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|
| Number of Participants Who Developed Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20) | 0 |
| Percentage of participants | SC Administration of IGIV, 10% With rHuPH20 |
|---|---|
| Percentage of Participants Who Developed Neutralizing Antibodies to Recombinant Human Hyaluronidase (rHuPH20) | 0.0 |
Further analysis for incidences of potential hemolysis included direct Coombs' test, free hemoglobin, serum haptoglobin, LDH, urine hemosiderin and microscopic urinalysis
| Number of participants | Participants in Safety Data Analysis Set |
|---|---|
| Number of Participants Who Experienced a Hemoglobin Drop of >2.0 g/dL, With Evidence of Hemolysis on Further Analysis | 0 |
Further analysis for incidences of potential hemolysis included direct Coombs' test, free hemoglobin, serum haptoglobin, LDH, urine hemosiderin and microscopic urinalysis
| Percentage of participants | Participants in Safety Data Analysis Set |
|---|---|
| Percentage of Participants Who Experienced a Hemoglobin Drop of >2.0 g/dL, With Evidence of Hemolysis on Further Analysis | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IV Administration of IGIV, 10% | — | 3/87 (3.4%) | 67/87 (77%) |
| SC Administration of IGIV, 10%, With rHuPH20 (With Ramp-up) | — | 12/83 (14.5%) | 81/83 (97.6%) |
| Event | IV Administration of IGIV, 10% | SC Administration of IGIV, 10%, With rHuPH20 (With Ramp-up) |
|---|---|---|
| Adrenocortical Insufficiency AcuteEndocrine disorders | 0/87 | 1/83 |
| GastroenteritisInfections and infestations | 0/87 | 1/83 |
| Back InjuryInjury, poisoning and procedural complications | 0/87 | 1/83 |
| Grand Mal ConvulsionNervous system disorders | 0/87 | 1/83 |
| HeadacheNervous system disorders | 0/87 | 1/83 |
| Petit Mal EpilepsyNervous system disorders | 0/87 | 1/83 |
| Status EpilepticusNervous system disorders | 0/87 | 1/83 |
| Cervical DysplasiaReproductive system and breast disorders | 1/87 | 1/83 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/87 | 1/83 |
| Tonsillar HypertrophyRespiratory, thoracic and mediastinal disorders | 0/87 | 1/83 |
| Event | IV Administration of IGIV, 10% | SC Administration of IGIV, 10%, With rHuPH20 (With Ramp-up) |
|---|---|---|
| INFUSION SITE PAINGeneral disorders | 1/87 | 37/83 |
| SINUSITISInfections and infestations | 14/87 | 35/83 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 8/87 | 32/83 |
| HEADACHENervous system disorders | 24/87 | 27/83 |
| NAUSEAGastrointestinal disorders | 12/87 | 15/83 |
| FATIGUEGeneral disorders | 8/87 | 14/83 |
| INFUSION SITE ERYTHEMAGeneral disorders | 0/87 | 14/83 |
| ASTHMARespiratory, thoracic and mediastinal disorders | 7/87 | 14/83 |
| VOMITINGGastrointestinal disorders | 8/87 | 13/83 |
| PYREXIAGeneral disorders | 8/87 | 13/83 |
| Age, Continuous(years) | 2 to <12 Years | 12 Years and Older | Total |
|---|---|---|---|
| Median | 8.0 (4 to 11) | 44.0 (12 to 78) | 35.0 (4 to 78) |
| Sex: Female, Male(Participants) | 2 to <12 Years | 12 Years and Older | Total |
|---|---|---|---|
| Female | 6 | 37 | 43 |
| Male | 8 | 36 | 44 |
| Region of Enrollment(Participants) | 2 to <12 Years | 12 Years and Older | Total |
|---|---|---|---|
| United States | 14 | 72 | 86 |
| Canada | 0 | 1 | 1 |
Ran from Dec 2008 to primary completion in Nov 2010, 22 months.
Results were first posted in Dec 2015, 5 years after primary completion. A results delay was requested in Nov 2011.
Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 22 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hyaluronidase (human recombinant)
Primary Immunodeficiency Diseases →